

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053141 A2


- (51) International Patent Classification⁷: **A61K 31/00**
- (21) International Application Number: PCT/US01/48458
- (22) International Filing Date:
14 December 2001 (14.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/255,534 14 December 2000 (14.12.2000) US
- (71) Applicant: COLEY PHARMACEUTICAL GROUP, INC. [US/US]; Suite 101, 93 Worcester Street, Wellesley, MA 02481 (US).
- (72) Inventor: BRATZLER, Robert, L.; 84 Barns Hill Road, Concord, MA 01742 (US).
- (74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS



WO 02/053141 A2

(57) Abstract: The invention relates to methods and products for inhibiting angiogenesis. At least one antiangiogenic nucleic acid molecule is administered to a subject to prevent or treat unwanted angiogenesis. Non-nucleic acid antiangiogenic agents also can be administered.

- 1 -

INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS

Background of the Invention

Blood vessels are the means by which oxygen and nutrients are supplied to living

5 tissues and waste products are removed from living tissue. Angiogenesis refers to the process by which new blood vessels are formed. See, for example, the review by Folkman and Shing, *J. Biol. Chem.* 267(16):10931-10934, 1992. Thus, where appropriate, angiogenesis is a critical biological process. It is essential in reproduction, development and wound repair. However, inappropriate angiogenesis can have severe negative consequences. For example, it
10 is only after many solid tumors are vascularized as a result of angiogenesis that the tumors have a sufficient supply of oxygen and nutrients that permit it to grow rapidly and metastasize. Because maintaining the rate of angiogenesis in its proper equilibrium is so critical to a range of functions, it must be carefully regulated in order to maintain health. The angiogenesis process is believed to begin with the degradation of the basement membrane by
15 proteases secreted from endothelial cells (EC) activated by mitogens such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The cells migrate and proliferate, leading to the formation of solid endothelial cell sprouts into the stromal space, then, vascular loops are formed and capillary tubes develop with formation of tight junctions and deposition of new basement membrane.

20 In adults, the proliferation rate of endothelial cells is typically low compared to other cell types in the body. The turnover time of these cells can exceed one thousand days. Physiological exceptions in which angiogenesis results in rapid proliferation typically occurs under tight regulation, such as found in the female reproduction system and during wound healing.

25 The rate of angiogenesis involves a change in the local equilibrium between positive and negative regulators of the growth of microvessels. The therapeutic implications of angiogenic growth factors were first described by Folkman and colleagues over two decades ago (*Folkman, N. Engl. J. Med.* 285:1182-1186, 1971). Abnormal angiogenesis occurs when the body loses at least some control of angiogenesis, resulting in either excessive or
30 insufficient blood vessel growth. For instance, conditions such as ulcers, strokes, and heart attacks may result from the absence of angiogenesis normally required for natural healing. In contrast, excessive blood vessel proliferation can result in tumor growth, tumor spread, blindness, psoriasis and rheumatoid arthritis.

- 2 -

There are instances where a greater degree of angiogenesis is desirable, e.g., increasing blood circulation, wound healing, and ulcer healing. For example, recent investigations have established the feasibility of using recombinant angiogenic growth factors, such as fibroblast growth factor (FGF) family (Yanagisawa-Miwa et al., *Science*, 257:1401-1403, 1992; Baffour et al., *J. Vasc. Surg.* 16:181-91, 1992), endothelial cell growth factor (ECGF; Pu et al., *J. Surg. Res.* 54:575-83, 1993), and more recently, vascular endothelial growth factor (VEGF) to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia (Takeshita et al., *Circulation*, 90:228-234, 1994; Takeshita et al., *J. Clin. Invest.* 93:662-70, 1994).

Conversely, there are instances where inhibition of angiogenesis is desirable. For example, many diseases are driven by persistent unregulated angiogenesis, also sometimes referred to as "neovascularization". In arthritis, new capillary blood vessels invade the joint and destroy cartilage. In diabetes, new capillaries invade the vitreous of the eye, bleed, and cause blindness. Ocular neovascularization is the most common cause of blindness. Tumor growth and metastasis are angiogenesis-dependent. A tumor must continuously stimulate the growth of new capillary blood vessels for the tumor itself to grow.

The current approved treatment of these diseases is inadequate. Agents which prevent continued angiogenesis, such as drugs (e.g. TNP-470), monoclonal antibodies, antisense nucleic acids and proteins (e.g., angiostatin and endostatin) are currently being tested, but have not been approved. Although preliminary results with the antiangiogenic proteins are promising, they are relatively large in size and are difficult to use and produce. Moreover, proteins are subject to enzymatic degradation. Thus, new agents that inhibit angiogenesis are needed. New antiangiogenic agents that show improvement in size, ease of production, stability and/or potency would be desirable.

Summary of the Invention

It has now been discovered that nucleic acid molecules, including oligonucleotides, have intrinsic antiangiogenesis properties apart from the proteins such nucleic acids may encode.

According to one aspect of the invention, methods for inhibiting angiogenesis are provided. The methods include administering to a subject in need of such treatment at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis in the subject. In some embodiments, two or more antiangiogenic nucleic acid molecules are

- 3 -

administered. In other embodiments, non-nucleic acid antiangiogenic agents also are administered and agents that are effective against other aspects of an angiogenic condition (e.g., anticancer agents) can also be administered. In some embodiments, the angiogenesis is associated with a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation. In other embodiments, the angiogenesis is not associated with a cancer or tumor, but may be associated with an eye or ocular disorder such as those described herein. In still other embodiments, the angiogenesis is associated with embryo implantation. In certain embodiments, the angiogenesis is associated with conditions involving excessive or abnormal stimulation of endothelial cells such as but not limited to intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.

In other aspects of the invention, compositions are provided that include at least one antiangiogenic nucleic acid molecule, formulated in a pharmaceutically-acceptable carrier and in an effective amount for inhibiting angiogenesis. The compositions in certain embodiments include non-nucleic acid antiangiogenic agents and/or agents that are effective against other aspects of an angiogenic condition (e.g., anticancer agents).

According to still other aspects the invention, kits are provided that include a first container housing at least one antiangiogenic nucleic acid molecule and instructions for administering the antiangiogenic nucleic acid molecule to a subject having unwanted angiogenesis. In certain embodiments, a second container housing at least one non-nucleic acid antiangiogenic agent is also provided. In other embodiments of the foregoing kits, another container housing at least one anticancer agent is provided. In certain embodiments, the instructions relate to administering the antiangiogenic nucleic acid to a subject having a condition that is not cancer or a tumor, and examples of such conditions are listed throughout the specification.

A nucleic acid molecule is an element of each aspect of the invention. Preferred nucleic acid molecules include at least one sequence set forth as SEQ ID NOs: 1-1093. The nucleic acids useful according to the invention are synthetic or natural (isolated) nucleic acids. The nucleic acid may be administered alone or in conjunction with a pharmaceutically-acceptable carrier and optionally other therapeutic agents. In some embodiments the nucleic

- 4 -

acid is a CpG nucleic acid, including those having an unmethylated CpG motif, a T-rich nucleic acid, or a poly G nucleic acid.

The nucleic acid in some embodiments has a nucleotide backbone which includes at least one backbone modification, such as a phosphorothioate modification or other phosphate modification. In some embodiments the modified backbone is a peptide modified oligonucleotide backbone. The nucleotide backbone may be chimeric, or the nucleotide backbone is entirely modified.

The nucleic acid can have any length greater than 6 nucleotides, but in some embodiments is between 8 and 100 nucleotide residues in length. In other embodiments the nucleic acid comprises at least 20 nucleotides, at least 24 nucleotides, at least 27, nucleotides, or at least 30 nucleotides. The nucleic acid may be single stranded or double stranded. In some embodiments the nucleic acid is isolated and in other embodiments the nucleic acid may be a synthetic nucleic acid. The antiangiogenic nucleic acids in some instances are not antisense molecules.

The CpG nucleic acid in one embodiment contains at least one unmethylated CpG dinucleotide having a sequence including at least the following formula: 5' X₁ X₂CGX₃ X₄ 3' wherein C is unmethylated, wherein X₁, X₂, X₃, and X₄ are nucleotides. In one embodiment the 5' X₁ X₂CGX₃ X₄ 3' sequence of the CpG nucleic acid is a non-palindromic sequence, and in other embodiments it is a palindromic sequence.

In some embodiments X₁X₂ are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X₃X₄ are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In other embodiments X₁X₂ are GpA or GpT and X₃X₄ are TpT. In yet other embodiments X₁ or X₂ or both are purines and X₃ or X₄ or both are pyrimidines or X₁X₂ are GpA and X₃ or X₄ or both are pyrimidines. In one embodiment X₂ is a T and X₃ is a pyrimidine.

In other embodiments the CpG nucleic acid has a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447,

- 5 -

448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In some embodiments the T rich nucleic acid is a poly T nucleic acid comprising 5' TTTT 3'. In yet other embodiments the poly T nucleic acid comprises 5' X₁ X₂TTTX₃ X₄ 3' wherein X₁, X₂, X₃ and X₄ are nucleotides. In some embodiments X₁X₂ is TT and/or X₃X₄ is TT. In other embodiments X₁X₂ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and/or X₃X₄ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

The T rich nucleic acid may have only a single poly T motif or it may have a plurality of poly T nucleic acid motifs. In some embodiments the T rich nucleic acid comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 T motifs. In other embodiments it comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 CpG motifs. In some embodiments the plurality of CpG motifs and poly T motifs are interspersed.

In yet other embodiments at least one of the plurality of poly T motifs comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 contiguous T nucleotide residues. In other embodiments the plurality of poly T motifs is at least 3 motifs and wherein at least 3 motifs each comprises at least 3 contiguous T nucleotide residues or the plurality of poly T motifs is at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

The T rich nucleic acid may include one or more CpG motifs. The motifs may be methylated or unmethylated. In other embodiments the T rich nucleic acid is free of one or more CpG dinucleotides.

In other embodiments the T rich nucleic acid has poly A, poly G, and/or poly C motifs. In other embodiments the T rich nucleic acid is free of two poly C sequences of at least 3 contiguous C nucleotide residues. Preferably the T rich nucleic acid is free of two poly A sequences of at least 3 contiguous A nucleotide residues. In other embodiments the T rich nucleic acid comprises a nucleotide composition of greater than 25% C or greater than 25%

- 6 -

A. In yet other embodiments the T rich nucleic acid is free of poly-C sequences, poly G sequences or poly-A sequences.

In some cases the T rich nucleic acid may be free of poly T motifs, but rather, comprises a nucleotide composition of greater than 25% T. In other embodiments the T rich nucleic acid may have poly T motifs and also comprise a nucleotide composition of greater than 25% T. In some embodiments the T rich nucleic acid comprises a nucleotide composition of greater than 25% T, greater than 30% T, greater than 40% T, greater than 50% T, greater than 60% T, greater than 80% T, or greater than 90% T nucleotide residues. The T rich nucleic acid in some embodiments is selected from the group consisting of SEQ ID NOs: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T rich nucleic acids are sequence selected from the group consisting of SEQ ID NOs: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In some embodiments the poly G nucleic acid comprises: 5' X₁X₂GGGX₃X₄ 3' wherein X₁, X₂, X₃, and X₄ are nucleotides. In embodiments at least one of X₃ and X₄ are a G or both of X₃ and X₄ are a G. In other embodiments the poly G nucleic acid comprises the following formula: 5' GGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In yet other embodiments the poly G nucleic acid comprises the following formula: 5' GGGNGGGNGGG 3' wherein N represents between 0 and 20 nucleotides. The poly G nucleic acid in some embodiments is selected from the group consisting of SEQ ID NOs.: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes a sequence selected from the group consisting of SEQ ID NOs; 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

The poly G nucleic acid may include one or more CpG motifs or T-rich motifs. The CpG motifs may be methylated or unmethylated. In other embodiments the poly G nucleic acid is free of one or more CpG dinucleotides or poly-T motifs.

- 7 -

The nucleic acid molecules and optionally other agents may be administered by any route known in the art for delivering medicaments. The medicaments may be administered separately or together, in the same pharmaceutical formulation or separate formulations, by the same route or by different routes. In one embodiment the nucleic acid molecule(s) is
5 administered on a routine schedule. In another embodiment the other agent(s) (e.g., antiangiogenesis agents, anticancer agents) is administered on a routine schedule.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

!0

Brief Description of the Drawings

Figure 1 is a histogram showing the effect of a CpG nucleic acid on angiogenesis as measured by hemoglobin content.

The drawing is not required for enablement of the claimed invention.

15

Detailed Description of the Invention

The present invention includes compositions that include antiangiogenic nucleic acids and methods of using the antiangiogenic nucleic acids for the treatment of diseases that are mediated by angiogenesis. The invention includes antiangiogenic nucleic acids having
20 various nucleotide sequences. The present invention comprises a method of treating undesired angiogenesis in a human or animal comprising the steps of the administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of, for example, an antiangiogenic nucleic acid.

As used herein, the term "angiogenesis" means the generation of new blood vessels
25 into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The term "endothelium" means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels. The term
30 "endothelial inhibiting activity" means the capability of a molecule to inhibit angiogenesis in general and, for example, to inhibit the growth of bovine capillary endothelial cells in culture in the presence of fibroblast growth factor.

- 8 -

Antiangiogenic nucleic acids are effective in treating diseases or processes that are mediated by, or involve, angiogenesis. The present invention includes the method of treating an angiogenesis mediated disease with an effective amount of antiangiogenic nucleic acids. The angiogenesis mediated diseases include, but are not limited to, solid tumors; blood born tumors such as leukemias; tumor metastasis; benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; pre-malignant tumors; rheumatoid arthritis; psoriasis; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation.

Antiangiogenic nucleic acids may be useful in the treatment of disease of excessive or abnormal stimulation of endothelial cells. These diseases include, but are not limited to, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.

Antiangiogenic nucleic acid can be used as a birth control agent by preventing vascularization required for embryo implantation.

Antiangiogenic nucleic acids may be useful in the treatment of conditions characterized by abnormal epithelial cell proliferation, such as proliferative dermatologic disorders. These include conditions such as keloids, seborrheic keratosis, papilloma virus infection (e.g. producing verruca vulgaris, verruca plantaris, verruca plana, condylomata, etc.) and eczema.

Antiangiogenic nucleic acids may be useful in the treatment of precancerous lesions such as epithelial precancerous lesions. An epithelial precancerous lesion is a lesion of epithelial cell origin that has a propensity to develop into a cancerous condition. An example is a precancerous skin lesion. Epithelial precancerous skin lesions also arise from other proliferative skin disorders such as hemangiomas, keloids, eczema and papilloma virus infections producing verruca vulgaris, verruca plantaris and verruca planar. The symptoms of the epithelial precancerous lesions include skin-colored or red-brown macule or papule with dry adherent scales. Actinic keratosis is the most common epithelial precancerous lesion among fair skinned individuals. It is usually present as lesions on the skin which may or may not be visually detectable. The size and shape of the lesions varies. It is a photosensitive disorder and may be aggravated by exposure to sunlight. Bowenoid actinic keratosis is another form of an epithelial precancerous lesion. In some cases, the lesions may develop

- 9 -

into an invasive form of squamous cell carcinoma and may pose a significant threat of metastasis. Other types of epithelial precancerous lesions include hypertrophic actinic keratosis, arsenical keratosis, hydrocarbon keratosis, thermal keratosis, radiation keratosis, viral keratosis, Bowen's disease, erythroplasia of queyrat, oral erythroplasia, leukoplakia,
5 and intraepidermal epithelialoma.

Antiangiogenic nucleic acids may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with surgery, radiation or chemotherapy combined with antiangiogenic nucleic acids and then antiangiogenic nucleic acids may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize any residual primary tumor. In some instances it may be preferable to administer the antiangiogenic nucleic acids specifically to a site likely to harbor a metastatic lesion (that may or may not be clinically discernible at the time). A sustained release formulation implanted specifically at the site (or the tissue) where the metastatic lesion is likely to be would be suitable in these latter instances.
10

15 In some embodiments, the antiangiogenic nucleic acids of the invention do not interfere with specific receptor-ligand interactions at the cell surface of a cell, thereby causing the stimulation or inhibition of signaling through such receptors. These interactions include those involving heparin binding receptor, VEGF receptor, or EGF receptor.

In still other embodiments, the antiangiogenic nucleic acids are not antisense nucleic acids, meaning that they do not function by binding to complementary genomic DNA or RNA species within a cell and thereby inhibiting the function of said genomic DNA or RNA species. In important embodiments, the antiangiogenesis nucleic acid does not comprise a nucleic acid sequence that corresponds to a VEGF encoding sequence (or is complementary to a VEGF encoding sequence).
20

25 The effective dosage for inhibition of angiogenesis *in vivo*, which can be defined as inhibition of capillary endothelial cell proliferation and/or migration and/or blood vessel ingrowth, can be extrapolated from *in vitro* inhibition assays. *In vitro* assays have been developed to screen for inhibition of angiogenesis. Events that can be tested to assess angiogenesis inhibitors include proteolytic degradation of extracellular matrix and/or basement membrane, proliferation of endothelial cells, migration of endothelial cells, and capillary tube formation. The chick chorioallantoic membrane assay (CAM), described by Taylor and Folkman (*Nature* 297:307-312, 1982), can be used to determine whether the compound is capable of inhibiting neovascularization *in vivo*.
30

- 10 -

In some embodiments, the antiangiogenic nucleic acids are administered in doses, routes and schedules (and also in therapeutic cocktails) that would not result in the stimulation of an immune response.

The effective dosage is dependent not only on the sequence of the nucleic acid
5 molecules used for inhibition of angiogenesis, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor preferably is delivered in a topical or ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor preferably is delivered by means of a biodegradable, polymeric implant.

10 An "antiangiogenic nucleic acid" as used herein is any nucleic acid containing an antiangiogenic motif or backbone that inhibits capillary endothelial cell proliferation and/or migration and/or blood vessel ingrowth.

The compounds useful according to the invention are nucleic acids. The nucleic acids may be double-stranded or single-stranded. Generally, double-stranded molecules may be
15 more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)) or a modified base. As used
20 herein, the terms refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e. a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules as used herein include vectors, e.g., plasmids, as well as oligonucleotides.

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or
25 oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus
30 the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

- 11 -

The substituted purines and pyrimidines of the nucleic acids include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases (Wagner et al., *Nature Biotechnology* 14:840- 844, 1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 5 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to 10 one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

15 Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' → 3' order from left to right and that "A" denotes adenosine, "C" denotes cytosine, "G" denotes guanosine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Nucleic acid molecules useful according to the invention can be obtained from natural 20 nucleic acid sources (e.g. genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g. produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic 25 acid encompasses both synthetic and isolated nucleic acids.

The term "isolated" as used herein refers to a nucleic acid which is substantially free of or which is separated from components which it is normally associated with in nature e.g., nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids are sufficiently pure and are 30 sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid of the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation, the nucleic acid may comprise only a small percentage by weight of the

- 12 -

preparation. The nucleic acid is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems. The nucleic acids can be produced on a large scale in plasmids, (see Sambrook, T., *et al.*, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor laboratory Press, New York, 1989) and 5 separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the nucleic acids can be synthesized *de novo* using 10 any of a number of procedures well known in the art. For example, the β -cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054, 1986; Froehler *et. al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986, ; Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986, 15 Gaffney *et al.*, *Tet. Let.* 29:2619-2622, 1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

In some embodiments, the nucleic acids useful according to the invention may function as immunostimulatory nucleic acids. An immunostimulatory nucleic acid is any nucleic acid, as described herein, which is capable of modulating an immune response. A nucleic acid which modulates an immune response is one which produces any form of 20 immune stimulation, including, but not limited to, induction of a cytokine, B cell activation, T cell activation, monocyte activation. Immunostimulatory nucleic acids include, but are not limited to, CpG nucleic acids, T-rich nucleic acids, poly G nucleic acids, and nucleic acids having phosphate modified backbones, such as phosphorothioate backbones.

A "CpG nucleic acid" or a "CpG antiangiogenic nucleic acid" as used herein is a 25 nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e. "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and inhibits angiogenesis. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

30 In one embodiment the invention provides a CpG nucleic acid represented by at least the formula:



- 13 -

wherein X₁ and X₂ are nucleotides and N is any nucleotide and N₁ and N₂ are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X₁ is adenine, guanine, or thymine and/or X₂ is cytosine, adenine, or thymine. In other embodiments X₁ is cytosine and/or X₂ is guanine.

5 In other embodiments the CpG nucleic acid is represented by at least the formula:



wherein X₁, X₂, X₃, and X₄ are nucleotides. In some embodiments, X₁X₂ are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X₃X₄ are nucleotides selected from the group consisting of: TpT, 10 CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA; N is any nucleotide and N₁ and N₂ are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments, X₁X₂ are GpA or GpT and X₃X₄ are TpT. In other embodiments X₁ or X₂ or both are purines and X₃ or X₄ or both are pyrimidines or X₁X₂ are GpA and X₃ or X₄ or both are pyrimidines.

15 In another embodiment the CpG nucleic acid has the sequence




Examples of CpG nucleic acids according to the invention include but are not limited to those listed in Table 1, such as SEQ ID NOs: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-20 141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-25 485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 30 888-904, and 909-913.

A "T rich nucleic acid" or "T rich antiangiogenic nucleic acid" is a nucleic acid which includes at least one poly T sequence and/or which has a nucleotide composition of greater than 25% T nucleotide residues and which inhibits angiogenesis. A nucleic acid having a

- 14 -

poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. Preferably the T rich nucleic acid includes more than one poly T sequence. In preferred embodiments the T rich nucleic acid may have 2, 3, 4, etc poly T sequences, such as SEQ ID NO:246 or SEQ ID NO:433. Other T rich nucleic acids have a nucleotide composition of greater than 25% T nucleotide residues, but do not necessarily include a poly T sequence. In these T rich nucleic acids the T nucleotide resides may be separated from one another by other types of nucleotide residues, i.e., G, C, and A. In some embodiments the T rich nucleic acids have a nucleotide composition of greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 99%, T nucleotide residues and every integer % in between. Preferably the T rich nucleic acids have at least one poly T sequence and a nucleotide composition of greater than 25% T nucleotide residues.

In one embodiment the T rich nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In one embodiment X_1X_2 is TT and/or X_3X_4 is TT. In another embodiment X_1X_2 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and X_3X_4 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

In some embodiments it is preferred that the T-rich nucleic acid does not contain poly C (CCCC), poly A (AAAA), poly G (GGGG), CpG motifs, or multiple GGs. In other embodiments the T-rich nucleic acid includes these motifs. Thus in some embodiments of the invention the T rich nucleic acids include CpG dinucleotides and in other embodiments the T rich nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or unmethylated.

Examples of T rich nucleic acids that are free of CpG nucleic acids include but are not limited to those listed in Table 1, such as SEQ ID Nos: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913.

Examples of T rich nucleic acids that include CpG nucleic acids include but are not limited to those listed in Table 1, such as SEQ ID Nos: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

- 15 -

Poly G containing nucleic acids are also useful in accordance with the invention. A "poly G nucleic acid" or "poly G antiangiogenic nucleic acid" is a nucleic acid which includes at least one poly G sequence and/or which has a nucleotide composition of greater than 25% G nucleotide residues and which inhibits angiogenesis. A variety of references, including
5 Pisetsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Macaya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogan, 1998, In Applied Antisense Oligonucleotide Technology, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.* 116, 991-994 describe the properties of poly G nucleic acids.

10 Poly G nucleic acids preferably are nucleic acids having the following formulas:



wherein X₁, X₂, X₃, and X₄ are nucleotides. In preferred embodiments at least one of X₃ and X₄ are a G. In other embodiments both of X₃ and X₄ are a G. In yet other embodiments the preferred formula is 5' GGGNGGG 3', or 5' GGGN_NGGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In other embodiments the Poly G nucleic acid is free of unmethylated CG dinucleotides, such as, for example, the nucleic acids listed below as SEQ ID Nos: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes at least one unmethylated CG dinucleotide, such as, for example, the nucleic acids listed above as SEQ ID Nos; 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

The antiangiogenic nucleic acids of the invention can also be those which do not possess CpG, poly-G, or T-rich motifs.

25 Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

30 The antiangiogenic nucleic acid molecules may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Nucleic acids can be produced on a large scale in

- 16 -

plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

“Palindromic sequence” shall mean an inverted repeat (i.e. a sequence such as ABCDEE’D’C’B’A’ in which A and A’ are bases capable of forming the usual Watson-Crick base pairs and which includes at least 6 nucleotides in the palindrome. *In vivo*, such sequences may form double-stranded structures. In one embodiment the nucleic acid contains a palindromic sequence. In some embodiments when the nucleic acid is a CpG nucleic acid, a palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome, and optionally is the center of the palindrome. In another embodiment the nucleic acid is free of a palindrome. A nucleic acid that is free of a palindrome does not have any regions of 6 nucleotides or greater in length which are palindromic. A nucleic acid that is free of a palindrome can include a region of less than 6 nucleotides which are palindromic.

A “stabilized nucleic acid molecule” shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3’ end of an oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized oligonucleotides of the instant invention have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the nucleic acids when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5’ end of the oligonucleotide and multiple phosphorothioate linkages at the 3’ end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail in PCT Published Patent Applications claiming priority to U.S. Patent Nos. 6,207,646B1 and 6,239,116B1, the entire contents of which are hereby incorporated by reference. It is believed that these modified oligonucleotides may show more antiangiogenic activity due to enhanced

- 17 -

nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.

Other stabilized oligonucleotides include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

For use *in vivo*, nucleic acids are preferably relatively resistant to degradation (*e.g.*, via endo-and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. One type of stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries.

Aryl-and alkyl-phosphonates can be made, *e.g.*, as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., *Chem. Rev.* 90:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Other sources of nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

In general, vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources. Viral vectors are one type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary

- 18 -

tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known to the art. Some viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with a nucleic acid to be delivered.

5 Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA.

Standard protocols for producing empty vectors or vectors carrying genes (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a 10 packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and/or infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

15 Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly 20 advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. Some plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pcDNA3.1, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation 25 reactions to remove and add specific fragments of DNA.

Exemplary antiangiogenic nucleic acid sequences include but are not limited to those antiangiogenic sequences shown in Table 1 (SEQ ID NO: 1 to SEQ ID NO:1093). The Table lists the SEQ ID NO, nucleotide sequence of the oligonucleotide (ODN sequence), and backbone modification, if any.

30 Backbone modifications are abbreviated as follows:

S = phosphorothioate

O = phosphodiester

SOS = phosphorothioate and phosphodiester chimeric with phosphodiester in middle

- 19 -

SO = phosphorothioate and phosphodiester chimeric with phosphodiester on 3' end

OS = phosphorothioate and phosphodiester chimeric with phosphodiester on 5' end

S2 = phosphorodithioate

S2O = phosphorodithioate and phosphodiester chimeric with phosphodiester on 3' end

5 OS2 = phosphorodithioate and phosphodiester chimeric with phosphodiester on 5' end

X = unknown

p-ethoxy = p-ethoxy backbone; see, e.g., US patent 6,015,886

PO = phosphodiester

ODN sequence symbols, other than a, c, g and t, are as follows:

10 i = inosine

n = a, c, g, or t

d = a, g or t

h = a, c or t

b = c, g or t; if "b" is single and is listed on 5' or 3' end of oligonucleotide, then "b"

15 indicates a biotin moiety attached to that end of the oligonucleotide

q = 5-methyl-cytosine

m = a or c

s = c or g

x = if "x" is single and is listed on 5' or 3' end of oligonucleotide, then "x" indicates a

20 biotin moiety attached to that end of the oligonucleotide

z = 5-methyl-cytidine

f = FITC moiety attached to 5' or 3' end of oligonucleotide

Table 1

SEQ ID NO:	ODN SEQUENCE	BACKBONE
1	tctcccagcggtgcggcat	S
2	ataatccagcttgaaccaag	S
3	ataatcgacgttcaagcaag	S
4	taccgcgtgcgaccctct	S
5	ggggagggt	S
6	ggggagggg	S
7	ggtgaggtg	S
8	tccatgtzgttcctgatgct	o
9	gctaccttagzgtga	o
10	tccatgazgttcctgatgct	o
11	tccatgacgttcztgatgct	o
12	gctagazgttagtgt	o
13	agctccatggtgctactg	s
14	ccacgtcgaccctcaggcga	s
15	gcacatcgccccgacgccga	s
16	gtcactcggttacctcga	s

- 20 -

17	gttggatacaggccagacttttgttgc	o
18	gattcaaccttgcgtcatcttaggc	o
19	accatggacgaactgtttccccctc	s
20	accatggacgagctgtttccccctc	s
21	accatggacgacgtttccccctc	s
22	accatggacgtactgtttccccctc	s
23	accatggacggctgtttccccctc	s
24	accatggacgtctgtttccccctc	s
25	ccactcacatctgtgtccacaag	o
26	acttctcatagtccttggtccag	o
27	tccatgagcttcctgagtct	o
28	gaggaaggigiggaiagacgt	o
29	gtgaaticgttcicgggict	o
30	aaaaaa	s
31	cccccc	s
32	ctgtca	s
33	tcgttag	s
34	tcgtgg	s
35	cgtcgt	s
36	tccatgtcggtcctgagtct	sos
37	tccatgccgtcctgagtct	sos
38	tccatgacggtcctgagtct	sos
39	tccatgacggtcctgagtct	sos
40	tccatgtcgatcctgagtct	sos
41	tccatgtcgctcctgagtct	sos
42	tccatgtcggtcctgagtct	sos
43	tccatgacgttcctgagtct	sos
44	tccataacgttcctgagtct	sos
45	tccatgacgtccctgagtct	sos
46	tccatcacgtgcctgagtct	sos
47	tccatgtcggtcctgagtct	sos
48	tccatgtzggtcctgagtct	sos
49	ccgcttcctccagatgagctcatgggttttccaccaag	o
50	cttggtgagaaaccatgagctcatctggaggaagcgg	o
51	ccccaaaggatgagaagtt	o
52	agatagcaaatcggtgacg	o
53	ggttcacgtgctcatggctg	o
54	tctcccacgtgcgccat	s
55	tctcccacgtgcgccat	s
56	taccgcgtgcgaccctct	s
57	ataatccagcttgaaccaag	s
58	ataatcgacgttcaagcaag	s
59	tccatgatttcctgatttt	o
60	ttgtttttttttttttttttttt	s
61	ttttttttttttttttttttt	o
62	tgctgctttgtgtttttttttt	s
63	tgctgctttgtgtttttttttt	o
64	gcattcatcaggcgggcaagaat	o
65	taccgagcttcgacgagattca	o
66	gcatgacgttgagct	s
67	cacgttgaggggcat	s
68	ctgctgagactggag	s
69	tccatgacgttcctgacgtt	s
70	gcatgacgttgagctga	o
71	tcagcgtgcgcc	s
72	atgacgttcctgacgtt	s
73	ttttgggtttttttttttttt	s

- 21 -

74	tctaggcttttaggctcc	s
75	tgcatttttaggccaccat	s
76	tctcccagcgtgcgtgcgccat	s
77	tctcccagcgccat	s
78	tctcccagcgagcgccat	s
79	tctcccagcgccat	s
80	ggggtaacgttcagggggg	sos
81	ggggtccacgcgtgcgccatgggg	sos
82	ggggtgtcgttcagggggg	sos
83	tccatgtcgttcctgtcgtt	s
84	tccatagcgttcctagcgtt	s
85	tcgtcgctgtctccgccttctt	s
86	gcatacggttgcgttgcgttgcgtt	Sos
87	tctcccagcgccat	Sos
88	tccatgazgttcctgazgtt	s
89	gcatacggttgcgttgcgttgcgtt	O
90	tccagcgtgcgcata	sos
91	tctcccagcgccat	O
92	tccatgagcttcctgagtc	O
93	gcatacggttgcgttgcgttgcgtt	sos
94	tcctgacgttcctgacgtt	s
95	gcatacggttgcgttgcgttgcgtt	O
96	gcatttcgaggagct	O
97	gcatacggttgcgttgcgttgcgtt	O
98	tccaggacgttcctagttct	O
99	tccaggacgttcctagttct	O
100	tccaggatgttcctagttct	O
101	tccagtctaggcctagttct	O
102	tccagttcgagcctagttct	O
103	gcatacggttgcgttgcgttgcgtt	sos
104	gcatacggttgcgttgcgttgcgtt	sos
105	gcatttcgaggagct	sos
106	gcatttcgaggagct	sos
107	tctcccagcgccat	sos
108	tctcccagcgccat	sos
109	tctcccagcgccat	sos
110	tctcccagcgccat	sos
111	tctcccagcgccat	sos
112	tctcccagcgccat	sos
113	gctandcghhagc	O
114	tcctgacgttccc	O
115	ggaagacgtttaga	O
116	tcctgacgtttaga	O
117	tcagaccagctgggtcggtgttctga	O
118	tcaggaacaccgcaccagctgggtctga	O
119	gctagtcgtatgc	O
120	gctagtcgtatgc	O
121	gcttgacgttgcgtatgc	O
122	gcttgacgttgcgtatgc	O
123	gcttgacgtcaagc	O
124	gctagacgttgcgtatgc	O
125	tccatgacattcctgtatgc	O
126	gctagacgttgcgtatgc	O
127	ggctatgtcggttcctagcc	O
128	ggctatgtcgatcctagcc	O
129	ctcatgggttctccaccaag	O
130	cttgggtggagaaacccatgag	O

- 22 -

131	tccatgacgttccatgttct	o
132	ccgcttcctccagatgagctcatg	o
133	catgagctcatctggaggaagcg	o
134	ccagatgagctcatgggttctcc	o
135	ggagaaacccatgagctcatctgg	o
136	agcatcaggaacgacatgga	o
137	tccatgacgttccgtacgtt	RNA
138	gcgcgcgcgcgcgcgcgc	o
139	ccggccgcgcgcgcgcgc	o
140	ttccaatcagccccaccgccttgccccaccctcaccccca	o
141	tggagggtgagggtggggccagagcggtgggtgtattggaa	o
142	tcaaatgtgggattttccatgagtct	o
143	agactcatggaaaatcccacattga	o
144	tgccaagtgtgagtcactaataaaga	o
145	tctttattatgtgactcagcaactggca	o
146	tgcaggaagtccgggtttccccaaaaacccccc	o
147	gggggggtggggaaaacccggacttcctgca	o
148	ggggactttccgctgggactttccaggggactttcc	Sos
149	tccatgacgttccctccatgacgttccctccatgacgttccctc	o
150	gaggaacgtcatggagaggaacgtcatggagaggaacgtcatgga	o
151	ataatagagctcaagcaag	s
152	tccatgacgttccgtacgtt	s
153	tccatgacgttccgtacgtt	sos
154	tccaggactttccctcaggtt	s
155	tcttgcgatgctaaggacgtcacattgcacaatcttaaagg	o
156	accttattaagattgtcaatgtgacgtcccttagcatcgcaaga	o
157	tcctgacgttccctggcggtccctgtcgct	o
158	tcctgtcgctccgtcgct	o
159	tcctgacgttgaagt	o
160	tcctgtcggttgaagt	o
161	tcctggcggttgaagt	o
162	tcctgccgttgaagt	o
163	tccttaacgttgaagt	o
164	tcctaacgttgaagt	o
165	tcctcaacgttgaagt	o
166	tcctgacgttgaagt	o
167	tcctgacgttgaagt	o
168	tcctgacgttgaagt	o
169	tcctgacgttgaagt	o
170	tcctgacgttcaagt	o
171	tcctgacgttgaagt	o
172	tcctgacgttgaagt	o
173	gggggacgttgggg	o
174	tcctgacgttcccttc	o
175	tctcccaacgcgagcgagcgccat	s
176	tcctgacgttccctggcggtccctgtcgct	o
177	tcctgtcgctccgtcgctccgtcgct	o
178	tcctggcggttgaagt	o
179	tcctgazgttgaagt	o
180	tcztgacgttgaagt	o
181	tccttagcgttgaagt	o
182	tccagacgttgaagt	o
183	tcctgacgttgaagt	o
184	tcctggcggttgaagt	o
185	ggctccggggagggattttgcata	o
186	atagacaaaaattccctccccggagcc	o
187	tccatgacgttccgtacgtt	RNA

- 23 -

188	tcgtcgctgtctccgcttctt	so
189	tcgtcgctgtctccgcttctt	s20
190	tcgagacattgcacaatcatctg	o
191	cagattgtgcaatgtctcg	o
192	tccatgtcggtcctgatgcg	o
193	gcgatgtcggtcctgatgc	o
194	gcgatgtcggtcctgatgcg	o
195	tccatgtcggtccgcgcgc	o
196	tccatgtcggtcctgcgc	o
197	tccatgtcggtcctgttagct	o
198	gcggcggggcggcgcgcgc	o
199	atcaggaacgtcatggaaagc	o
200	tccatgaggttcctgagtct	p-ethoxy
201	tcaacgtt	p-ethoxy
202	tcaagctt	p-ethoxy
203	tcctgtcggttcctgtcg	s
204	tccatgtcggttttgtcg	s
205	tcctgtcggttcctgtcg	s
206	tcctgtcggttcctgtcg	s
207	btccattccatgacgttcctgatgctcca	os
208	tcctgtcggttttgtcg	s
209	tcgtcgctgtctccgcttctt	s
210	tcgtcgctgtctgccttctt	s
211	tcgtcgctgttgtcg	s
212	tcctgtcggttcctgtcggtggaaacgacagg	o
213	tcctgtcggttcctgtcggttcaacgtcaggaaacgacagg	o
214	ggggtctgtcggtttgggggg	sos
215	ggggtctgtcggtttgggggg	sos
216	tccggccgttgaagt	o
217	tccggacggtgaagt	o
218	tcccggccgttgaagt	o
219	tccagacggtgaagt	o
220	tcccggacggtgaagt	o
221	tccagagcttgaagt	o
222	tccatgtzgttcctgtzgt	s
223	tccatgacgttcctgacgtt	sos
224	ggggttgacgtttgggggg	sos
225	tccaggacttctctcaggtt	s
226	tttttttttttttttttttt	s
227	tccatgccgttcctgcgtt	s
228	tccatggcgccgttgcgg	s
229	tccatgacgttcctgcgtt	s
230	tccatgacgttcctggcg	s
231	tccatgacgttcctgcgtt	s
232	tccatgacggtgcgtacgg	s
233	tccatgctgcgtgcgttt	s
234	tccatgctgcgtgcgtt	s
235	Btccattccattctaggcctgagtctccat	os
236	tccatagcggttcctagcg	o
237	tccatgtcggttcctgtcg	o
238	tccatagcgatccatcgat	o
239	tccattgcgttcctgcgtt	o
240	tccatagcggttcctagcg	o
241	tccatgatttcctgcagttcctgat	ttt
242	tccatgacgttcctgcagttcctgacgtt	s
243	ggcggcggcggcggcggcgg	o
244	tccacgacgtttcgacgtt	s

- 24 -

245	tgcgttgtcggtcggt	s
246	tgcgttttgcgttttcgtt	s
247	tgcgttgtcggttcgtt	s
248	gcgtgcgttgtcggttcgtt	s
249	czggczggczggczccgg	o
250	gccccccccccccccccccc	s
251	agccccgigaacgaiattcac	o
252	tgtcgtttgcgttttcgtt	s
253	tgtcgtttgcgttgtcggttcgtt	s
254	tgtcgtttgcgttgtcggttcgtt	s
255	tgcgtcgctcggt	s
256	tgtcgtttgcgtt	s
257	cccccccccccccccccccc	s
258	tctagcgttttagcgttcc	sos
259	tgcattcccccaggccaccat	s
260	tcgtcgctcgctcgctcggtt	sos
261	tcgtcgtttgcgttgtcggtt	sos
262	tcgtcgtttgcgttgttcgtt	sos
263	tcgtcgtttgcgttgttcgtt	sos
264	ggggaggggaggaaactcttaaaaattcccccagaatgttt	o
265	aaacattctgggggaattttaaagaagttccctccctcccc	o
266	atgttacttcttaaaaattcccccagaatgttt	o
267	aaacattctgggggaattttaaagaagtaaacat	o
268	atgttactagacaaaattcccccagaatgttt	o
269	aaacattctgggggaattttgtctagtaaacat	o
270	aaaatttgacgtttaaaaaa	sos
271	cccccttgacgttttcccccc	sos
272	ttttcggttgttttgcgtt	
273	tcgtcgtttgcgttgttcgtt	sos
274	ctgcagccgtggac	o
275	acccgtcgtaattatacgaaaaaccc	o
276	ggtacctgtggggacattgtg	o
277	agcaccgaacgtgagagg	o
278	tccatgccgttctggcgtt	o
279	tccatgacgggtctgacgggt	o
280	tccatgccgggtctggcgtt	o
281	tccatgcgcgttctggcgtt	o
282	ctggtctttctggtttttctgg	s
283	tcagggggtggggggaaacctt	sos
284	tccatgazgttccctagttct	o
285	tccatgatgttccctagttct	o
286	cccgaaagtcatccctttaacctgg	o
287	ccaggttaagagggaaatgacttgggg	o
288	tcctggzggggaaagt	o
289	gzggzgggzggzgzzgcccc	x
290	tccatgtgttccctgtatgt	o
291	tccatgtcttccctgtatgt	
292	tccatgtgttccctagttct	
293	tccaagttagttccctagttct	o
294	tccatgttagttccctagttct	o
295	tcccgccgttcccgccgtt	s
296	tcctggcggttccgggtt	s
297	tcctggaggggaaagt	o
298	tcctggggggaaagt	o
299	tcctgggtggggaaagt	o
300	tgcgttgttcgttgttcgtt	o
301	ctggtctttctggtttttctgg	o

- 25 -

- 26 -

359	gggttcaagttgagggggg	sos
360	tgcgtctcccccccccccc	s
361	tgcgtcgctcgcttt	s2
362	tgcgtcgctcgcttt	s20
363	tgcgtcgctcgcttt	os2
364	tcaacgtga	s
365	tcaacgtt	s
366	atagtttccattttttac	
367	aatagtgcgcategcgcgac	o
368	aatagtgcgcateccgggac	o
369	aatagtgcgcateccccccc	o
370	tgcgtctttgtgcctttgtcgtt	o
371	ctgtgcttcgtgttttctgtg	s
372	ctaatttctaaattttttctaa	s
373	tgcgtgggtgcgttgtgtcgtt	s
374	tgcgtgggtgcgttgtttgtt	s
375	accatggacgagctgtttccctc	
376	tgcgtttgcgtgcgttt	s
377	ctgtaagttagcttggagag	
378	gagaacgtggacactcc	
379	cgggcgactcagtcatacg	
380	gttctcagataaaggcggaaaccagcaacagacacagaa	
381	ttctgtgtctgttgcgttgtccgtttatctgagaac	
382	cagacacagaagcccgatagacg	
383	agacagacacgaaacgaccg	
384	gtctgtcccatgtatctcgaa	
385	gctggccagcttacctcccg	
386	ggggccttataacaacctggg	
387	ggggccctttagactgccc	
388	gagaacgtggacactccat	
389	tccatgtcggtctgtatgt	
390	ctcttgcacactggaaaggta	
391	aggtagccaggactacga	
392	accatggacgacactgtttccctc	
393	accatggattacctttccctt	
394	atggaaaggccaggcttc	o
395	agcatcaggaccgacatgg	o
396	ctctccaagctcaattacag	
397	tccctgagactggcccacctt	
398	gccaccaaaactgtccatg	
399	gtccatggcgtgcgggatgta	
400	cctctataacaacctgggac	
401	cgggcgactcagtcatacg	
402	gcgttacccgttgcgttgcgt	
403	cgactgccaacaggatatcggtgatcagcactgg	
404	ccagtgcgtatcaccgatatcctgttcggcagtcg	
405	ccagggttatagaggc	
406	tctcccacgcgtacgcct	s
407	tctcccacgcgtgcgttt	s
408	tctcccacgcgtgcgcct	s
409	tctcccacgcgtgcgcct	s
410	ataatcgctgttcaagcaag	s
411	tgcgtttgtcggtttgtcgt	s2
412	tgcgtttgtcggtttgtcgt	s2
413	tgcgtttgtcggtttgtcgt	s2
414	tcntcgtnntncgtntncgt	s
415	tctcccacgcgtgcct	s

- 27 -

416	tctcccatcgccat	s
417	ataatcgccgttcaagaaag	s
418	ataatcgacgtccccccc	s
419	tctatcgacgttcaagcaag	s
420	tcc tga cgg gg agt	s
421	tccatgacgttcgtatcc	
422	tccatgacgttcgtatcc	
423	tcacatgacgttcgtatcc	
424	tcc tgg cgt gga agt	s
425	tccatgacgttcgtatcc	
426	tcgtcgctgttgcgtttctt	s
427	agcagcttagatgttagagtt	s
428	cccccccccccccccccccccc	s
429	tcgtcgctgttgcgtttgtcg	s
430	tcgtcgctgttgcgtttgtcg	s
431	tcgtcgcttttttttttttt	s
432	tttttcaacgttgcattttt	sos
433	tttttttttttttttttttt	S
434	ggggtcgtcgcccccccccc	
435	tcgtcgctgtcgcccccccc	
436	tcgtcgctgtctccgcgttcttgcc	s
437	tcgtcgctgtctccgc	s
438	ctgttaagttagtggagag	
439	gagaacgtggacccat	
440	ccagggttatagaggc	
441	gctagacgttagcgtga	
442	ggagcttcgtacgcacccata	
443	tctccatgtggttatcg	
444	aagggtggggcagtctcaggga	
445	atcgaggactggcgcgcgg	
446	ttaggacaaggcttaggggt	
447	accacaacgagaggAACGCA	
448	ggcagtgcaggctcacccgg	
449	gaaccttcatgtgtt	
450	gctagacgttagcgtga	
451	gcttggaggccgttaagt	
452	gtagccttccta	
453	cggtagccttccta	
454	cacggtagccttccta	
455	agcacggtagccttccta	
456	gaacgtggacccat	
457	gaccctccat	
458	tggacccat	
459	gctggacccat	
460	acgctggacccat	
461	taagctctgtcaacgcagg	
462	gagaacgtggacccatgt	
463	tccatgtcggtctgtatgt	
464	ttcatgcctgaaaaatggcg	
465	tgcttagctgtgcctgtaccc	
466	agcatcaggaccgacatgg	
467	gaccctccatgtcggtctgtat	
468	acaaccacgagaacggggAAC	
469	gaaccttcatgtgttccg	
470	caatcaatctgaggagaccc	
471	tcagctctggtaacttttca	
472	tggttacggctgtccccatg	

- 28 -

473	gtctatcgaggactggcgc	
474	cattttacggcgccccggc	
475	gaggggaccattttacgggc	
476	tgtccagccgaggggaccat	
477	cgggcttacggcgatgctg	
478	tggaccttctatgtcggtcc	
479	tgtcccatttttagaaagc	
480	gtggttacggtcgtgccccat	
481	cctccaaatgaaaagaaaaaa	
482	ttgtactctccatgtatggtt	
483	ttccatgtgtccggctgg	
484	gaccttcatgtcggtcctg	
485	gagaccgctcgacccttcgat	
486	ttgccccatatttttagaaac	
487	ttgaaaactgaggtggac	
488	ctatcgaggactggcgcc	
489	cttggagggcctcccgccgg	
490	gctgaaccttccatgtgtt	
491	tagaaacagcatttttttagggcagcaca	
492	agatggttctcagataaagcgaa	
493	ttcccgcttatctgagaaccatct	
494	gtcccaggttgatagaggctgc	
495	gcgcgcagtcctccgatagac	
496	atcgaggactggcgcccg	
497	ggtctgtccatatttttag	
498	tttttcaacgttgggggg	sos
499	tttttcaagcggttatttttt	sos
500	ggggtaaacgttgggggg	sos
501	ggggttttcaacgtttgggggg	sos
502	gttacggctgtccatata	
503	ctgtccatatttttagaca	
504	accatcctgaggccattcg	
505	cgtctatcggttctgtgtctg	
506	ggccatcccacatttggaa	
507	ccaaatatcggtggtaagcac	
508	gtgcttggaccaccatatttgg	
509	gtgctgtatccgatatcctgttcgg	
510	ggccaacttcaatgtggatggcctc	
511	ttccgcgcgaatggcctcaggatggtac	
512	tatagtccctgagactgccccaccttctcaacaacc	
513	gcagcctctataacaacctggacggga	
514	ctatcgaggactggcgcc	
515	tatcgaggactggcgcc	
516	gatcgaggactggcgcc	
517	ccgaacaggatatcggtgatcagcac	
518	ttttggggtaacgttgggggg	
519	ggggtaacgttgggggg	sos
520	cgcgcgcgcgcgcg	s
521	ggggcatgacgttgggggg	ss
522	ggggcatgacgttaaaaaaaa	s
523	ggggcatgacgttgggggg	s
524	ggggcatgacgttgggggg	sos
525	aaaacatgacgttaaaaaaaa	sos
526	aaaacatgacgttgggggg	sos
527	ggggcatgacgttaaaaaaaa	sos
528	accatggacgatctgtttccccctc	s
529	gccatggacgaaactgttccccctc	s

- 29 -

530	cccccccccccccccccccc	sos
531	gggggggggggggggggg	sos
532	gctgtaaaatgaatcgccg	sos
533	ttcggggggactccatt	sos
534	tatgccgcggacttat	sos
535	ggggtaatcgatcaggggg	sos
536	tttggaaacgtggaccc	sos
537	gatcgctgatctaattcg	sos
538	gtcggtccatgtcggttcc	sos
539	tctcgctcagttcgctcg	sos
540	ctggacccatcgatcg	sos
541	gctcggtcagcgctct	sos
542	ctggacccatcgatcg	sos
543	cactgtcctcgatcg	sos
544	cgctggacccatcgatcg	sos
545	gctgagctcatcgatcg	sos
546	aacgctggacccatcg	sos
547	tgcattgttgcatacagct	sos
548	ccttcatgtcggtccat	sos
549	tactcttcggatccatcg	sos
550	ttccatgtcggtccat	sos
551	ctgattgtctctcgat	sos
552	ggcgttatttcgtactcg	o
553	cctacgttgatcgcccgat	o
554	ggggtaatcgatcgaggggg	o
555	ttcggggggactccatt	o
556	tttttttttttttttttt	o
557	gggggttttttttttttt	o
558	tttttgggggggggggtttt	o
559	gggggggggggggggggt	o
560	aaaaaaaaaaaaaaaaaa	o
561	cccccaaaaaaaaaaaaa	o
562	aaaaacccccccccaaaa	o
563	tttgaattcaggactggtaggttag	o
564	tttgaatccatcgccgtccat	o
565	aattcttatcggttctgtgttgtgtttttttat	o
566	ctagataaagcggaaccaggacaacagacacagaagccccatagag	o
567	ttttcttagagagggtgcacaatgtctgg	o
568	tttgaattccgttacagaagcgagac	o
569	tttgcggccgttagacttaacctgagagata	o
570	tttggggccacgagagacagacacttc	o
571	tttggggccgttctcgcttctgtacacg	o
572	gagaacgctggacccat	s
573	tccatgtcggtccat	s
574	ctgtcg	s
575	tcgtga	s
576	cgtcga	s
577	agtgcgt	s
578	ctgtcg	o
579	agtgcgt	o
580	cgtcga	o
581	tcgtga	o
582	gagaacgctccagctcgat	o
583	gctagacgtaaacgtga	o
584	gagaacgctcgacccat	o
585	gagaacgctggacccat	o
586	gctagaggtaggtcgat	o

- 30 -

587	gagaacgctggacttccat	o
588	tcacgctaacctcttagc	o
589	bgctagacgttagcgta	o
590	atggaaggctcgagcgttctc	o
591	gagaacgctggacccctcgat	o
592	gagaacgatggacccctccat	o
593	gagaacgctggatccat	o
594	gagaacgctccacgtactgat	o
595	tccatgtcggtccctcgat	o
596	atgtcctcggtccctcgat	o
597	gagaacgctccacccctccat	o
598	gagaacgctggacccctcgta	o
599	batgaaaggccacgcgttctc	o
600	tcctga	o
601	tcaacgtt	o
602	aacgtt	o
603	aacgttga	o
604	tcacgctaaccctcttagc	o
605	gagaacgctggacccctcgat	o
606	gctggacccctccat	o
607	gagaacgctggacccatccat	o
608	gagaacgctggacccatccat	o
609	aacgttggggggcat	o
610	atgcccctcaacgtt	o
611	tcaacgttga	o
612	gctggacccctccat	o
613	caacgtt	o
614	acaacgttga	o
615	tcacgt	o
616	tcaagctt	o
617	tcgtca	o
618	aggatatac	o
619	tagacgtc	o
620	gacgtcat	o
621	ccatcgat	o
622	atcgatgt	o
623	atgcatgt	o
624	ccatgcat	o
625	agcgctga	o
626	tcagcgct	o
627	ccttcgat	o
628	gtgccggggctccggggc	s
629	gctgtggggcggtccctg	s
630	btcaacgtt	o
631	ftcaacgtt	o
632	faacgttga	o
633	tcaacgt	s
634	aacgttg	s
635	cgacga	o
636	tcaacgtt	o
637	tcgga	o
638	agaacgtt	o
639	tcatcgat	o
640	taaacgtt	s
641	ccaacgtt	s
642	gctcga	s
643	cgacgt	s

- 31 -

644	cgtcgt	s
645	acgtgt	s
646	cgttcg	s
647	gagcaagctggacccatccat	s
648	cgcgta	s
649	cgtacg	s
650	tcaccggt	s
651	caagagatgctaacaatgca	s
652	acccatcaatacgctctgtgc	s
653	ccatcgat	o
654	tcgacgtc	o
655	ctagcgct	o
656	taagcgct	o
657	tgcgaaattcgcg	o
658	atggaaagggtccagcgttct	o
659	actggacgtttagcgtga	o
660	cgcctggggctggctctgg	o
661	gtgtcggggctctccgggc	o
662	gtgccgggtctccgggc	o
663	cgcgcgtcgcggcggttgg	o
664	gaagttcacgttgaggggcat	o
665	atctggtgaggggcaagctatg	s
666	gttggaaacccgagaacatcat	s
667	gcaacgtt	o
668	gtaacgtt	o
669	cgaacgtt	o
670	gaaacgtt	o
671	caaacgtt	o
672	ctaacgtt	o
673	ggaacgtt	o
674	tgaacgtt	o
675	acaacgtt	o
676	ttaacgtt	o
677	aaaacgtt	o
678	ataaacgtt	o
679	aacgttct	o
680	tccgatcg	o
681	tccgtacg	o
682	gctagacgttagcgtga	o
683	gagaacgtggacccatcatccat	o
684	gagaacgttagacccatctat	o
685	actagacgttagtgtga	o
686	cacacttggtaatgtcacgt	o
687	tctccatcctatggtttatcg	o
688	cgctggacccat	o
689	caccacccgttcaatgtcacgt	o
690	gctagacgttagctgga	o
691	agtgcgattgcagatcg	o
692	ttttcggtttgtggttgtggtt	
693	ttttcggtttgtcggtttgtcggtt	
694	tttttgggtttgtggttgtggtt	
695	accgcgtggattctaggcca	s
696	gctagacgttagcgt	o
697	aacgcgtggacccat	o
698	tcaazgtt	o
699	ccttcgat	o
700	actagacgttagtgtga	s

- 32 -

701	gctagaggtagcgta	s
702	atggactctccagcgtttc	o
703	atcgactctcgagcgtttc	o
704	gctagacgttagc	o
705	gctagacgt	o
706	agtgcgattcgagatcg	o
707	tcazagct	o
708	ctgattgtctctcgta	o
709	tzaacgtt	o
710	gagaazgctggacccat	o
711	gctagacgttaggcgtga	o
712	gctacttagcgta	o
713	gctacccgtcgta	o
714	atcgacttcgagcgtttc	o
715	atgcactctgcagcgtttc	o
716	agtgcactctccagcgtttc	o
717	gccagatgttagctgga	o
718	atcgactcgagcgtttc	o
719	atcgatcgagcgtttc	o
720	bgagaacgctcgaccctcgat	o
721	gctagacgttagctgga	sos
722	atcgactctcgagcgtttc	sos
723	tagacgttagcgta	o
724	cgactctcgagcgtttc	o
725	ggggtcgacccctggagggggg	sos
726	gctaacgttagcgta	o
727	cgtcgctgt	o
728	gagaacgctggacccat	o
729	atcgacctacgtgcgttztc	o
730	atzgacccatcggtcggttc	o
731	gctagazgttagcg	o
732	atcgactctcgagzgttc	o
733	ggggtaatgcatacgggggg	sos
734	ggctgttattccgtactgccc	s
735	ccatgcataacctctagc	o
736	gctagatgttagcgta	o
737	cgtacccatcggtga	o
738	tccatgtggtcctgatgct	o
739	atcgactctctcgagcgtttc	o
740	gctagagcttagcgta	o
741	atcgactctcgagtggttc	o
742	aacgctcgacccat	o
743	ctcaaacgctggacccat	o
744	atcgacctacgtgcgttc	o
745	gagaatgtggacccat	o
746	tcacgcataacctctgac	o
747	bgagaacgctccagcactgat	o
748	bgagcaagctggacccat	o
749	cgctagaggtagcgta	o
750	gctagatgttaacgt	o
751	atggaaagggtccacgttc	o
752	gctagatgttagcg	o
753	gctagacgttagtgc	o
754	tccatgacggtcctgatgct	o
755	tccatggcggtcctgatgct	o
756	gctagacgatagcg	o
757	gctagtcgatagcg	o

- 33 -

758	tccatgacgttccctgatgct	o
759	tccatgtcggtccctgatgct	o
760	gctagacgttagzgt	o
761	bctaggcgtagcggt	o
762	tccatgtzggtcctgatgct	o
763	tccatgtcggtzctgatgct	o
764	atzgactctzgagzgttctc	o
765	atggaaaggccactgttctc	o
766	gcatgacgttgagct	o
767	ggggtaacaacgttgagggggg	s
768	ggggtaacaacgttgagggggg	sos
769	cgcgcgcgcgcgcgcgcgc	o
770	cccccccccccccccccccccccc	s
771	cccccccccccccccccccccccc	s
772	tccatgtcgatcctgatct	o
773	gctaaacgttagcggt	o
774	tccatgtcgatcctgatgct	o
775	tccatgcggtcctgatgct	o
776	aaaaatacaacgttgaaaaaaaa	sos
777	tccataaacgttccctgatgct	o
778	tggaggcccaccgagatcgag	o
779	cgtcgtcgtcgtcgtcgt	s
780	ctgctgtcgtcgtcgt	s
781	gagaacgctccgacattcgat	s
782	gctagatgttagcggt	s
783	gcatgacgttgagct	s
784	tcaatgtcgaf	o
785	tcaacgttgaf	o
786	tcaacgttgab	o
787	gcaatattgcb	o
788	gcaatattgcf	o
789	agttgcaact	o
790	tcttcgaa	o
791	tcaacgtc	o
792	ccatgtcggtccctgatgct	o
793	gttttttatataatttgg	o
794	tttttgttgcgtttgtcggtt	o
795	ttgggggggggtt	s
796	ggggttgggggtt	s
797	gggtgttaggttttgg	o
798	bgagaazgctcgacattcgat	o
799	tcaacgttaacgttaacgtt	o
800	bgagcaagztggacattccat	o
801	bgagaazgctccagactgat	o
802	tcaazgttgax	o
803	gzaatattgcx	o
804	tgctgctttgtcggttgcct	o
805	ctgcgttagcaatttaactgt	o
806	tccatgacgttccctgatgct	s
807	tgcgtccgtgcacccgtacacagctct	s
808	tgcgtccgtacacagctct	s
809	tgcgtacgtct	s
810	tgcgtct	s
811	cccccccccccccccccccc	s
812	cccccccccccc	s
813	cccccccc	s
814	tgcgtacgtct	sos

- 34 -

815	tgcacgtccgtacacagctct	o
816	gagcaagctggacccat	s
817	tcaacgttaacgttaacgttaacgttaacgtt	s
818	gagaacgctcgaccctcgat	s
819	gtccccattttcccgaggaggaaat	o
820	ctagcggctgacgtcatcaagctag	o
821	ctagcttgatgacgtcagccgttag	o
822	cggctgacgtcatcaa	s
823	ctgacgtg	o
824	ctgacgtcat	o
825	attcgatcccccccccccccccc	o
826	ctcgcccccccccccccccc	o
827	gactgacgtcagegt	o
828	ctagcggctgacgtcataaagctagc	s
829	ctagcttatgacgtcagccgttagc	s
830	ctagcggctgacgtcataaagctagc	s
831	ctagtggctgacgtcatcaagctag	s
832	tccaccacgtggctatgtct	s
833	ggaaatgaaagattttattataag	o
834	tctaaaaccatctattcttaaccct	o
835	agctcaacgtcatgc	o
836	ttaacgggttagcggtattggc	o
837	ttaagaccaataccgctaccaccc	o
838	gatctagtgtatggatcagccggatc	o
839	gatccggctgactcatcaactatgc	o
840	tccaagacgttcctgtatgtct	o
841	tccatgacgtccctgtatgtct	o
842	tccaccacgtggctgtatgtct	o
843	ccacgtggacacctctagc	o
844	tcagaccacgtggctgggtgttctga	o
845	tcaggaacacccgaccacgtggctga	o
846	catttccacgatttccca	o
847	tccctctctgtcaagagact	o
848	tgtatctctgtcaaggact	o
849	ataaaagcggaaactagcagcagtttcc	o
850	gaaactgctgtatgtttcgctttat	o
851	tgcggccaaagaggaaaatttgcatacag	o
852	ctgtatgaaacaaaatttccctttggc	o
853	ttaggggttaggggttaggggtt	s
854	tccatgagcttcctgtatgtct	s
855	aaaacatgacgttcaaaaaaa	s
856	aaaacatgacgttcccccccc	s
857	ggggcatgagcttcccccccc	sos
858	ctaggctgacgtcatcaagctag	o
859	tctgacgtcatctgacgtggctgacgtct	o
860	ggaatttagtaatagatataagaatgtt	o
861	tttacctttataaacataactaaaacaaa	o
862	gcgttttttttgcg	s
863	atatctaataaaaaacattaacaaa	o
864	tctatcccagggtggctctgttag	o
865	btccatgacgttcctgtatgtct	o
866	btccatgagcttcctgtatgtct	o
867	ttttttttttttf	o
868	ttttttttttttf	sos
869	ctagcttgatgagctcagccgttag	o
870	ttcagttgtctgtctgttagctaa	o
871	tccatgagcttcctgtatgtct	s

- 35 -

872	ctagcggtgacgtcatcaatctag	o
873	tgcttagtgcgtgttacct	s
874	atgcataaaggacgtcacattgca	o
875	tgcaatgtgacgtcccttagcat	o
876	gtagggacttccgagctcgagatcctatg	o
877	cataggatctcgagctcgaaagtcccctac	o
878	ctgtcaggaactgcaggttaagg	o
879	cataacattaggaatatttactcctcgc	o
880	ctccagctccaagaaaggacg	o
881	gaagtttctggtaaagtcttcg	o
882	tgctgcttttgtgccttgcgtt	s
883	tcgtcgccccgtgtgtgtgtgtt	s
884	tcgtcgccccgtgtgtgtgtgtt	s
885	tcctgacgttcggcgccgcgc	s
886	tgctgcttttgtgccttgcgtt	
887	tccatgagcttcctgagctt	s
888	tcgtcgccccgtgtgtgtgtgtt	s
889	tcgtcgccccgtgtgtgtgtgtt	s
890	tcgcgtcgccccgtgtgtgtgtgtt	s
891	ttcgtcgccccgtgtgtgtgtgtt	s
892	tcctgacggggaaagt	s
893	tcctggcggttgaagt	s
894	tcctggcggttgaagt	s
895	tcctggcggttgaagt	s
896	tcctgacgttggaaagt	s
897	gcgacgttcggcgccgcgc	s
898	gcgacggggggcgccgcgcgc	s
899	gcggcggtcgccccgtgcgcgc	s
900	gcggcggtcgccccgtgcgcgc	s
901	gcgacgtcgccccgtgcgcgc	s
902	gcggcggtcgccccgtgcgcgc	s
903	gcgacgtcgccccgtgcgcgc	s
904	tcgtcggtgtctccg	s
905	tgtgggggtttttttttttgg	s
906	agggggagggggagggggaggggg	s
907	tgtgtgtgtgtgtgtgtgtgt	s
908	ctctctctctctctctctctct	sos
909	ggggtcgacgtcgaggggggg	s
910	atatatatatatatatatatat	s
911	ttttttttttttttttttttttttt	s
912	ttttttttttttttttttttttt	s
913	ttttttttttttttttt	s
914	gctagagggggaggg	
915	gctagatgtttaggg	
916	gcatgagggggagct	
917	atggaaagggtccagggggctc	
918	atggactctggagggggctc	
919	atggaaagggtccaagggggctc	
920	gagaaggggggaccttggat	
921	gagaaggggggaccttccat	
922	gagaaggggggccagcactgat	
923	tccatgtggggcctgatgct	
924	tccatgagggggcctgatgct	
925	tccatgtggggcctgatgat	
926	atggactctccgggggttctc	
927	atggaaagggtccgggggttctc	
928	atggactctggagggggtctc	

- 36 -

929	atggaggcgtccatgggctc	
930	atggactctgggggttctc	
931	tccatgtgggtgggatgct	
932	tccatgcgggtgggatgct	
933	tccatgggggtcctgatgct	
934	tccatggggtccctgatgct	
935	tccatgggggtcctgatgct	
936	tccatgggggtcctgatgct	
937	tccatgggggtcctgatgct	
938	gctagagggagtgt	
939	tttttttttttttttttt	s
940	gmggtaacgttgagggmogg	s
941	ggggagttcggttgggggggg	s
942	tgcgtttttccccccccccc	s
943	ttgggggggttttttttttttt	s
944	tttaaattttaaaattttaaaata	s
945	ttggttttttgtttttttttgg	s
946	tttccctttttcccccccccc	s
947	ggggtcatcgatgagggggg s	sos
948	tccatgacgttccctgacgtt	
949	tccatgacgttccctgacgtt	
950	tccatgacgttccctgacgtt	
951	tccatgacgttccctgacgtt	
952	tccatgacgttccctgacgtt	
953	tccatgacgttccctgacgtt	
954	tccatgacgttccctgacgtt	
955	tccatgacgttccctgacgtt	
956	tccatgacgttccctgacgtt	
957	tccatgacgttccctgacgtt	
958	tccatgacgttccctgacgtt	
959	gggggacatcggtggggg	sos
960	gggggtcgtaacgacgggggg	sos
961	tttttttttttttttttttt	po
962	aaaaaaaaaaaaaaaaaaaaaa	po
963	cccccccccccccccccccccc	po
964	tgcgttttgcgtttgcgtt	
965	tgcgttttgcgtttgcgtt	
966	tgcgttttgcgtttgcgtt	
967	tgcgttttgcgtttgcgtt	
968	ggggtaacgttgagggggg	
969	ggggtaacgttgagggggg	
970	ggggtaacgttgagggggg	
971	tgcgttttgcgtttgcgtt	
972	ggggacgtcgacgtgggggg	sos
973	ggggtcgtcgacgagggggg	sos
974	ggggtcgacgtacgtcgaggggg	sos
975	ggggaccggtaaccgggtggggg	sos
976	gggtcgacgtcgagggggg	sos
977	ggggtcgacgtcgagggggg	sos
978	ggggaacgttaacgtgggggg	sos
979	ggggtcaccgggtgagggggg	sos
980	ggggtcgttcgaacgagggggg	sos

- 37 -

981	ggggacgttgcAACGTGGGGGG	sos
982	tcaacttga	s
983	tcaagcttga	s
984	tcacgatcgta	s
985	tcagcatcgta	s
986	gggggagcatgtgggggggg	sos
987	gggggggggggggggggggggg	sos
988	gggggacatatacgtcgggggg	sos
989	gggggacacgtcgtcgggggg	sos
990	gggggacagctcgtcgggggg	sos
991	gggggacgtacgtcggggggg	sos
992	tcaacgtt	
993	tccataccggtcctgatgct	
994	tccataccggtcctaccgg	s
995	gggggacatcggtgggggggg	sos
996	ggggacatcgtcgggggggg	sos
997	ggg ggg acg atc gtc ggg ggg	sos
998	ggg gga cga tcg tcg ggg ggg	sos
999	aaa gac gtt aaa	po
1000	aaagagctaaa	po
1001	aaagazgttaaa	po
1002	aaattcggaaaa	po
1003	gggggtcatcgatgagggggg	sos
1004	gggggtcaacgttgggggggg	sos
1005	atgttagcttataacaaggc	po
1006	ggatccctttagtttacttct	po
1007	ccattccacttctgattacc	po
1008	tatgtatttatcatgttagata	po
1009	agcctacgtattcacccctcc	po
1010	ttccctgcactactattgtt	po
1011	atagaaggccctacaccagt	po
1012	ttacaccggctatggaggt	po
1013	ctaaccagatcaagtctagg	po
1014	cctagactttagtctgggttag	po
1015	tataagcctcgccgacatg	po
1016	catgtcgacgaggctata	po
1017	tgggtggggggagtaagctc	po
1018	gagctactccccaccaccca	po
1019	gccttcgatttcggtggga	po
1020	tggacttctttggcgct	po
1021	atgctgttagcccagcgataa	po
1022	accgaatcagcggaaagtga	po
1023	tccatgacgttccgtacgtt	
1024	ggagaaaacccatgagctcatctgg	
1025	accacagaccaggcaggcaga	
1026	gagcgtgaactgcgcgaaga	
1027	tcggtacccttgcagcggtt	
1028	ctggagccctagccaaggat	
1029	gcgactccatcaccagcgat	
1030	cctgaagtaagaaccagatgt	

- 38 -

1031	ctgtgttatctgacatacacc	
1032	aattagccttaggtgattggg	
1033	acatctgttctacttcagg	
1034	ataagtcatatttggaaactac	
1035	cccaatcacctaaggctaatt	
1036	ggggtcgtcgacgagggggg	sos
1037	ggggtcgttcgaacgagggggg	sos
1038	ggggacgttgcgaacgtgggggg	sos
1039	tcctggcqggagaqt	s
1040	ggggAACGACGTCGTTGGGGGG	sos
1041	ggggAACGTACGTACGTTGGGGGG	sos
1042	ggggAACGTACGTACGTTGGGGGG	sos
1043	ggggtcaccggtgagggggg	sos
1044	ggggtcgacgtacgtcgagggggg	sos
1045	ggggaccggtaaccggtgagggggg	sos
1046	gggtcgacgtcgagggggg	sos
1047	ggggtcgacgtcgaggggg	sos
1048	ggggAACGTTAACGTTGGGGGG	sos
1049	ggggacgtcgacgtggggg	sos
1050	gcactcttcgaagctacagccggcagcctctgat	
1051	cggctctccatgaggtcttgctaatcttgg	
1052	cggctctccatgaaagtcttggacgatgtgagc	
1053	tcctgcaggtaagt	s
1054	gggggtcggtcggtgggggg	sos
1055	gggggatgattgtgggggg	sos
1056	gggggazgatzgtgggggg	sos
1057	gggggagctagctgggggg	sos
1058	ggttctttggtccttgtct	s
1059	ggttctttggtcctcgct	s
1060	ggttctttggtccttatct	s
1061	ggttcttggtttccttgtct	s
1062	tggtctttggtccttgtct	s
1063	ggttcaaatggtccttgtct	s
1064	gggtctttggccttgtct	s
1065	tccaggactctctcaggttttt	s
1066	tccaaaactctctcaaatt	s
1067	tactactttatactttatactt	s
1068	tgtgtgtgtgtgtgtgtgt	s
1069	ttgtgtgtgttttgttgttg	s
1070	ggctccggggagggaaattttgtctat	s
1071	gggacgatcgctcggggggg	sos
1072	gggtcgctcgacgaggggggg	sos
1073	ggtcgtcgacgaggggggg	sos
1074	gggtcgctcgctgtggggggg	sos
1075	ggggacgatcgctcggggggg	sos
1076	ggggacgtcgctgtggggggg	sos
1077	ggggtcgacgtcgacgtcgaggggggg	sos
1078	ggggAACCGCGGTGGGGGG	sos
1079	ggggacgacgtcggtgggggg	sos
1080	tcgtcgctcgctgtgggggg	sos

- 39 -

Nucleic acids having modified backbones also are included in the class of nucleic acids having antiangiogenic properties. Modified backbone nucleic acids include those having phosphorothioate, methylphosphonate, methylphosphorothioate, p-ethoxy and/or phosphorodithioate internucleotide or internucleoside bonds. Chimeric oligonucleotides having mixtures of modified and/or unmodified backbones also are included in the invention.

In the case when an antiangiogenic nucleic acid is administered in conjunction with a nucleic acid vector, it is preferred that the backbone of the antiangiogenic nucleic acid be a chimeric combination of phosphodiester and phosphorothioate bonds (or other modification of the internucleotide bonds). This is because the uptake of the plasmid vector by the cell may be hindered by the presence of completely phosphorothioate oligonucleotide. Thus when both a vector and an oligonucleotide are delivered to a subject, it is preferred that the oligonucleotide have chimeric or phosphorothioate internucleotide bonds and that the plasmid be associated with a vehicle that delivers it directly into the cell, thus avoiding the need for cellular uptake. Such vehicles are known in the art and include, for example, liposomes, electroporation devices and gene guns.

For use in the instant invention, the antiangiogenic nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. Such compounds are referred to as "synthetic nucleic acids." For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054, 1986; Froehler *et al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986, Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986, Gaffney *et al.*, *Tet. Let.* 29:2619-2622, 1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

- 40 -

Alternatively, nucleic acids can be produced on a large scale in plasmids, (see, e.g., Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. Nucleic acids can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases. Nucleic acids prepared in this manner are referred to as isolated nucleic acids. The term "antiangiogenic nucleic acid" encompasses both synthetic and isolated antiangiogenic nucleic acids.

For use *in vivo*, nucleic acids are preferably relatively resistant to degradation (e.g., are stabilized). A "stabilized nucleic acid molecule" as used herein means a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Antiangiogenic nucleic acids that are tens to hundreds of kilobases long are relatively resistant to *in vivo* degradation. For shorter antiangiogenic nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of a nucleic acid is self-complementary to an upstream region of the same nucleic acid, so that it can fold back and form a stem/loop structure by internal self-hybridization, then the nucleic acid may be stabilized and therefore may exhibit more *in vivo* activity.

Alternatively, nucleic acid stabilization can be accomplished via backbone modifications. Preferred stabilized nucleic acids of the instant invention have a modified backbone. It has been demonstrated that modification of the nucleic acid backbone provides enhanced activity of the antiangiogenic nucleic acids when administered *in vivo*. One type of modified backbone is a phosphate backbone modification. For example, antiangiogenic nucleic acids including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5 or more, can in some circumstances protect the nucleic acid from degradation by intracellular exo- and endo-nucleases and thereby provide maximal activity. Other phosphate modified nucleic acids include phosphodiester modified nucleic acids, combinations of phosphodiester and phosphorothioate nucleic acids, methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy and combinations thereof. Some of these combinations in CpG nucleic acids and their particular effects on immune cells is discussed in more detail in PCT Published Patent Applications PCT/US95/01570 and PCT/US97/19791, the entire contents of which are hereby incorporated by reference. Although not intending to be bound by any

- 41 -

particular theory, it is believed that these modified nucleic acids may have increased activity relative to unmodified nucleic acids due to enhanced nuclease resistance, increased cellular uptake; increased protein binding, and/or altered intracellular localization.

Modified backbone nucleic acids, such as those having phosphorothioate bonds may 5 be synthesized using automated techniques employing, for example, phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863. Alkylphosphotriesters, in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574, can be prepared by automated solid phase synthesis using commercially available reagents. Methods 10 for making other nucleic acid backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., *Chem. Rev.* 90:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Another type of modified backbone, useful according to the invention, is a peptide 15 nucleic acid. The backbone is composed of aminoethylglycine and supports bases which provide the nucleic acid character. The backbone does not include any phosphate and thus may optionally have no net charge. The lack of charge allows for stronger DNA-DNA binding because the charge repulsion between the two strands does not exist. Additionally, because the backbone has an extra methylene group, the oligonucleotides are enzyme/protease 20 resistant. Peptide nucleic acids can be purchased from various commercial sources, e.g., Perkin Elmer, or synthesized de novo.

Another class of backbone modifications include 2'-O-methylribonucleosides (2'-O-Me). These types of substitutions are described extensively in the literature and in particular 25 with respect to their immunostimulating properties in Zhao et al., *Bioorganic and Medicinal Chemistry Letters*, 1999, 9:24:3453. Zhao et al. describes methods of preparing 2'-O-Me modifications to nucleic acids.

The nucleic acid molecules of the invention may include naturally-occurring or 30 synthetic purine or pyrimidine heterocyclic bases as well as modified backbones. Purine or pyrimidine heterocyclic bases include, but are not limited to, adenine, guanine, cytosine, thymidine, uracil, and inosine. Other representative heterocyclic bases are disclosed in US Patent No. 3,687,808, issued to Merigan, et al. The terms "purines" or "pyrimidines" or "bases" are used herein to refer to both naturally-occurring or synthetic purines, pyrimidines or bases.

- 42 -

Other stabilized nucleic acids include non-ionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acids which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either 5 or both termini have also been shown to be substantially resistant to nuclease degradation.

The antiangiogenic nucleic acids having backbone modifications useful according to the invention in some embodiments are S- or R-chiral antiangiogenic nucleic acids. An "S chiral antiangiogenic nucleic acid" as used herein is an antiangiogenic nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a 10 plurality of the chiral centers have S chirality. An "R chiral antiangiogenic nucleic acid" as used herein is an antiangiogenic nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a plurality of the chiral centers have R chirality. The backbone modification may be any type of modification that forms a chiral center. The modifications include but are not limited to phosphorothioate, 15 methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy, 2'-O-Me and combinations thereof.

The chiral antiangiogenic nucleic acids must have at least two nucleotides within the nucleic acid that have a backbone modification. All or less than all of the nucleotides in the nucleic acid, however, may have a modified backbone. Of the nucleotides having a modified backbone (referred to as chiral centers), a plurality have a single chirality, S or R. A 20 "plurality" as used herein refers to an amount greater than 50%. Thus, less than all of the chiral centers may have S or R chirality as long as a plurality of the chiral centers have S or R chirality. In some embodiments at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the chiral centers have S or R chirality. In other embodiments at least 55%, 60%, 25 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides have backbone modifications.

The S- and R- chiral antiangiogenic nucleic acids may be prepared by any method known in the art for producing chirally pure oligonucleotides. Stec et al teach methods for producing stereopure phosphorothioate oligodeoxynucleotides using an oxathiaphospholane. 30 (Stec, W.J., et al., 1995, *J. Am. Chem. Soc.*, 117:12019). Other methods for making chirally pure oligonucleotides have been described by companies such as ISIS Pharmaceuticals. US Patents which disclose methods for generating stereopure oligonucleotides include 5,883,237;

- 43 -

5,837,856; 5,599,797; 5,512,668; 5,856,465; 5,359,052; 5,506,212; 5,521,302; and 5,212,295, each of which is hereby incorporated by reference in its entirety.

As used herein, administration of an antiangiogenic nucleic acid is intended to embrace the administration of one or more antiangiogenic nucleic acids which may or may 5 not differ in terms of their profile, sequence, backbone modifications and biological effect. As an example, CpG nucleic acids and T-rich nucleic acids may be administered to a single subject along with other antiangiogenic medicament(s), such as endostatin or angiostatin. In another example, a plurality of CpG nucleic acids which differ in nucleotide sequence may also be administered to a subject.

10 The invention encompasses the administration of the antiangiogenic nucleic acids along with other medicaments in order to provide a synergistic effect useful in the prevention and/or treatment of conditions that involve unwanted angiogenesis, such as cancer. Accordingly, methods for inhibition of angiogenesis are provided. The methods include the administration of at least one antiangiogenic nucleic acid formulated for administration to a 15 subject. Non-nucleic acid antiangiogenesis molecules also can be administered to the subject, including, but not limited to endogenous angiogenesis inhibitors including PD 174073 and PD 166285 (Parke-Davis), SU5416 and SU6668 (Sugen), ZD 4190 and ZD 6474 (Zeneca), PTK 787 (also known as CGP79787 or ZK22584) (Novartis), Anti-VEGF mAb (Genentech), Anti-KDR mAb (ImClone), RPI 4610 (Ribozyme), TNP 470 (Abbott/TAP), AG 3340 (Agouron), 20 Marimastat (British Biotech), Bay 12-9566 (Bayer), Neovastat (Aeterna), BMS 275291 (Bristol Myers-Squibb), CGS 27023A (Novartis), D1927 Chiroscience), D2163 (Chiroscience), Isoquinolines (Pfizer), Vitaxin (IXSYS), S-137 (Searle), S-836 (Searle), SM256 (Dupont), SG545 (Dupont), Angiostatin (EntreMed), Endostatin (EntreMed), Thalidomide (EntreMed), Squalamine (Magainin), CAI (National Cancer Institute), CM-101 25 (CarboMed), U-995 (Gwo-Chyang GMP), Combretastatin A-4 (Oxogene), platelet factor-4, vasostatin, thrombospondin, tissue inhibitors of metalloproteinases (TIMPs), STI412 (Sun and McMahon, *Drug Discov. Today* 5(8):344-353, 2000; Klohs and Hamby, *Curr. Opin. Biotechnol.* 10:544-549, 1999), fumagillin, non-glucocorticoid steroids and heparin and heparin fragments and antibodies to one or more angiogenic peptides such as α -FGF, β -FGF, 30 VEGF, IL-8, and GM-CSF. Some of the foregoing may be administered in the form of nucleic acids encoding proteins; in each case the active agent is a protein and not the nucleic acid encoding the protein.

- 44 -

The antiangiogenic nucleic acid molecules of the invention can be administered concurrently with, or sequentially with, the non-nucleic acid antiangiogenesis molecules described above. Coadministration may be in the form of administration of a composition containing both kinds of antiangiogenic agents, or a plurality of compositions, each of which 5 may contain one or more than one of the antiangiogenic agents.

The invention may be used in the treatment of cancer, but is not so limited. In these methods, an effective amount of at least one antiangiogenic nucleic acid is administered to a subject having cancer, or in other instances a subject at risk of developing cancer. Other non-nucleic acid antiangiogenesis molecules also can be administered, as described above. In 10 addition, in certain embodiments of the invention, anticancer molecules are administered in combination with the antiangiogenesis molecules.

The compounds useful in the invention may be delivered in a mixture with anti-proliferative agents (particularly anticancer agents) which are not antiangiogenic nucleic acids. One of ordinary skill in the art is familiar with a variety of anti-proliferative agents 15 which are used in the medical arts to treat proliferative diseases such as cancer. These anti-cancer agents may act by directly killing cells, such as cancer cells (i.e., direct action anti-cancer agents), or alternatively they may act by sensitizing cells to direct action anti-cancer agents (i.e., indirect action anti-cancer agents). Those of skill in the art will recognize the distinction and are familiar with agents of either class. Anticancer agents include, but are not 20 limited to, the following sub-classes of compounds:

Antineoplastic agents such as: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Adriamycin; Aldesleukin ; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin ; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene 25 Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine ; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin ; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide ; Cytarabine ; Dacarbazine; DACA (N-[2-(Dimethyl-amino)ethyl]acridine-4-carboxamide); Dactinomycin; Daunorubicin 30 Hydrochloride; Daunomycin; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride ; Elsamitruclin; Enloplatin; Enpromate; Epipropidine; Epirubicin

- 45 -

Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; 5-FdUMP; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; 5 Gemcitabine Hydrochloride; Gold Au 198 ; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a ; Interferon Alfa-2b ; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a ; Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride ; Lanreotide Acetate; Letrozole; Leuprolide Acetate ; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; 10 Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin 15 Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin ; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol ; Safingol Hydrochloride ; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; 20 Strontium Chloride Sr 89; Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxitrone; Testolactone; Thiamiprime; Thioguanine; Thiotepa; Thymitaq; Tiazofurin; Tirapazamine; Tomudex; TOP-53; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil 25 Mustard; Uredopa; Vapreotide; Verteporfin; Vinblastine; Vinblastine Sulfate; Vincristine; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride; 2-Chlorodeoxyadenosine; 2'- Deoxyformycin; 9-aminocamptotheacin; raltitrexed; N-propargyl-5,8-dideazafolic acid; 2- 30 chloro-2'-arabino-fluoro-2'-deoxyadenosine; 2-chloro-2'-deoxyadenosine; anisomycin; trichostatin A; hPRL-G129R; CEP-751; linomide.

Other anti-neoplastic compounds include: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecyphenol; adozelesin; aldesleukin;

ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin
5 glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide;
10 bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives (e.g., 10-hydroxy- camptothecin); canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins;
15 chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatan; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; daclizimab; decitabine; dehydrodidegnin B; deslorelin; dexifosfamide;
20 dextrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; discodermolide; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epothilones including desoxyepothilones (A, R = H; B, R = Me); epithilones; epristeride; estramustine
25 analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide; etoposide 4'-phosphate (etopofos); exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;
30 heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact; irsogladine;

- 47 -

isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; 5 lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprolol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; 10 mismatched double stranded RNA; mithracin; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A + mycobacterium cell wall sk; molidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial 15 cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone + pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; 20 ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; 25 plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; podophyllotoxin; porfimer sodium; porfiromycin; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated 30 hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhodium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A;

- 48 -

sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;
5 spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide;
10 tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase
15 inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer.

Anti-cancer Supplementary Potentiating Agents: Tricyclic anti-depressant drugs (e.g., imipramine, desipramine, amitryptyline, clomipramine, trimipramine, doxepin, nortriptyline, protriptyline, amoxapine and maprotiline); non-tricyclic anti-depressant drugs (e.g., sertraline, trazodone and citalopram); Ca⁺⁺ antagonists (e.g., verapamil, nifedipine, nitrendipine and caroverine); Calmodulin inhibitors (e.g., prenylamine, trifluoroperazine and clomipramine); Amphotericin B; Triparanol analogues (e.g., tamoxifen); antiarrhythmic drugs (e.g., quinidine); antihypertensive drugs (e.g., reserpine); Thiol depleters (e.g., bathione and sulfoximine) and Multiple Drug Resistance reducing agents such as Cremaphor EL. The compounds of the invention also can be administered with cytokines such as granulocyte colony stimulating factor.

Antiproliferative agent: Piritrexim Isethionate.
30 Radioactive agents: Fibrinogen I 125 ; Fludeoxyglucose F 18 ; Fluorodopa F 18 ; Insulin I 125; Insulin I 131; Iobenguane I 123; Iodipamide Sodium I 131 ; Iodoantipyrine I 131 ; Iodocholesterol I 131 ; Iodohippurate Sodium I 123 ; Iodohippurate Sodium I 125 ; Iodohippurate Sodium I 131 ; Iodopyracet I 125 ; Iodopyracet I 131 ; Iofetamine

- 49 -

Hydrochloride I 123 ; Iomethin I 125 ; Iomethin I 131 ; Iothalamate Sodium I 125 ;
Iothalamate Sodium I 131 ; Iotyrosine I 131; Liothyronine I 125; Liothyronine I 131;
Merisoprol Acetate Hg 197; Merisoprol Acetate Hg 203; Merisoprol Hg 197 ;
Selenomethionine Se 75 ; Technetium Tc 99m Antimony Trisulfide Colloid; Technetium Tc
5 99m Bicisate ; Technetium Tc 99m Disofenin ; Technetium Tc 99m Etidronate ; Technetium
Tc 99m Exametazime ; Technetium Tc 99m Furifosmin ; Technetium Tc 99m Gluceptate ;
Technetium Tc 99m Lidofenin ; Technetium Tc 99m Mebrofenin ; Technetium Tc 99m
Medronate ; Technetium Tc 99m Medronate Disodium; Technetium Tc 99m Mertiatide ;
Technetium Tc 99m Oxidronate ; Technetium Tc 99m Pentetate; Technetium Tc 99m
10 Pentetate Calcium Trisodium; Technetium Tc 99m Sestamibi ; Technetium Tc 99m
Siboroxime ; Technetium Tc 99m Succimer ; Technetium Tc 99m Sulfur Colloid ;
Technetium Tc 99m Teboroxime ; Technetium Tc 99m Tetrofosmin ; Technetium Tc 99m
Tiatide; Thyroxine I 125; Thyroxine I 131; Tolpovidone I 131 ; Triolein I 125; Triolein I 131.

The present invention further includes nucleic acid molecules formulated into a
15 pharmaceutical composition for the inhibition of angiogenesis. The pharmaceutical
compositions of the invention include those suitable for oral, rectal, nasal, topical (including
buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular,
intravenous, intratumoral and intradermal) administration.

The nucleic acids are delivered in effective amounts. In general, the term "effective
20 amount" of a nucleic acid refers to the amount necessary or sufficient to realize a desired
biologic effect. Specifically, the effective amount is that amount that reduces the rate or
inhibits altogether angiogenesis. For instance, when the subject bears a tumor having a blood
supply, an effective amount is that amount which decreases or eliminates all together the
blood supply to the tumor. Additionally, an effective amount may be that amount which
25 prevents an increase or causes a decrease in new blood vessels, e.g., those vessels supplying a
tumor. The effective amount may vary depending upon whether the antiangiogenic nucleic
acid is used alone or in combination with other therapeutics, or in single or multiple dosages.
In some instances, it is envisioned that the combination of antiangiogenic nucleic acids with
other therapeutic agents (which are themselves not antiangiogenic nucleic acids) can result in
30 a synergism between the two compound classes, and thereby would require less of one or both
compounds in order to observe the desired biologic effect. Combined with the teachings
provided herein, by choosing among the various active compounds and weighing factors such
as potency, relative bioavailability, patient body weight, severity of adverse side-effects and

- 50 -

preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. As mentioned above, the effective amount for any particular application can vary depending on such factors as the type of condition having unwanted angiogenesis being treated or prevented, the particular nucleic acid being administered (e.g. the number of unmethylated CpG motifs or their location in the nucleic acid), the use of another antiangiogenesis agent, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular nucleic acid molecule without necessitating undue experimentation.

Subject doses of the compounds described herein typically range from about 0.1 µg to 10 mg per administration, which depending on the application could be given hourly, daily, weekly, or monthly and any other amount of time therebetween. More typically doses range from about 10 µg to 5 mg per administration, and most typically from about 100 µg to 1 mg, with 2 - 4 administrations being spaced hours, days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any compound described herein the therapeutically effective amount can be initially determined from animal models, e.g. the animal models described herein or those well known in the art. A therapeutically effective dose can also be determined from human data for CpG nucleic acids which have been tested in humans (human clinical trials have been initiated and the results publicly disseminated) and for compounds which are known to exhibit similar pharmacological activities, such as other antiangiogenesis agents. Higher doses may be required for parenteral administration, as described above. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

For use in therapy, an effective amount of the nucleic acid can be administered to a subject by any mode that delivers the nucleic acid to a subject. "Administering" the

- 51 -

pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. Some routes of administration include but are not limited to oral, intranasal, intratracheal, inhalation, ocular, vaginal, rectal, parenteral (e.g. intramuscular, intradermal, intravenous, intratumoral or subcutaneous injection) and direct injection.

5 For oral administration, the compounds (i.e., antiangiogenic nucleic acid molecules and optionally other antiangiogenesis agents) can be delivered alone without any pharmaceutical carriers or formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. The term "pharmaceutically-acceptable carrier" means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of 10 the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction 15 which would substantially impair the desired pharmaceutical efficiency.

Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, 20 after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, 25 disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions.

Dragee cores may be provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl 30 pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

- 52 -

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate 5 and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

10 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray, from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, 15 trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

20 The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

25 Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers

- 53 -

or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

5 The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

10 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

15 The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

20 Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions may also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

25 The nucleic acid molecules and/or agents (*e.g.*, antiangiogenesis agents, anticancer agents) may be administered per se (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the

- 54 -

following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

The nucleic acids or other therapeutics useful in the invention may be delivered in mixtures with additional antiangiogenesis agent(s). A mixture may consist of several antiangiogenesis agents in addition to the nucleic acid.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular nucleic acid molecules or other agents selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compounds into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S.

- 55 -

Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; 5 partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In 10 addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation. In still other embodiments, the agents and nucleic acids are formulated with GELFOAM, a commercial product consisting of modified collagen fibers that degrade slowly.

The nucleic acid may be directly administered to the subject or may be administered in conjunction with a pharmaceutically acceptable carrier or a delivery vehicle. The nucleic acid 15 and optionally other therapeutic agents may be administered alone (e.g. in saline or buffer) or using any delivery vehicles known in the art. One type of delivery vehicle is referred to herein as a nucleic acid delivery complex. A "nucleic acid delivery complex" shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell 20 (e.g. dendritic cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to reduce significant uncoupling prior to internalization by 25 the target cell. However, the complex may be cleavable under appropriate conditions within the cell so that the nucleic acid may be released in a functional form.

The nucleic acid molecules may be delivered by non-invasive methods as described above. Non-invasive delivery of compounds is desirable for treatment of children, elderly, animals, and even adults and also to avoid the risk of needle-stick injury. Delivery vehicles 30 for delivering compounds to mucosal surfaces have been described and include but are not limited to: cochleates, emulsomes, ISCOMs, liposomes, live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, *Bacillus calmette-guerin*, *Shigella*, *Lactobacillus*), live viral vectors (e.g., *Vaccinia*, adenovirus, Herpes Simplex), microspheres, nucleic acid vaccines,

- 56 -

polymers (e.g. carboxymethylcellulose, chitosan), polymer rings, proteosomes, sodium fluoride, transgenic plants, virosomes, and virus-like particles.

Examples

5 **1. Background**

1.1. Angiogenesis

Angiogenesis describes the active biological process of blood vessel formation from pre-existing microvasculature (1, 2). In multi-celled organisms this is a highly organized and tightly regulated process that occurs normally during development, inflammation, and tissue repair. The importance of angiogenesis is reflected in the need of mammalian cells for oxygen and nutrients. Mammalian cells must be within a 200 µM distance of blood vessels, which is the diffusion limit for oxygen (3). Thus the overall driving factor for angiogenesis is the requirement for oxygen and nutrients. The normal regulation of angiogenesis is mediated by the balance between pro- and anti-angiogenic factors that are released in the tissues and are influenced by local environmental factors.

15 *1.2. Angiogenesis and neoplasms*

In a neoplastic situation, the balances of these pro- and anti-angiogenic factors are generally skewed in favor of angiogenesis. In this setting, angiogenesis is generally a highly disorganized and loosely regulated process that is an absolute requirement for the continued growth of neoplasms (3). Further, there is a direct correlation between the extent of vascularization found in neoplasms and the potential for metastasis (4).

20 *1.3. Angiogenesis and chemokines*

There are a number of pro- and anti-angiogenic factors that have been described to date (3). The focus of this analysis will be on the chemokines interferon- γ -inducible protein (IP-10) and monokine induced by interferon- γ (MIG). Chemokines are a collection of cytokines that possess chemoattracting properties (for review see (5)). Chemokines are classified on the basis of the motif displayed by the first two cysteine residues present in the protein (CXC, CC, C, or CX3C), and they signal through G-protein coupled, seven-transmembrane receptors. Initially identified for their influence on hemopoietic cell migration, chemokines are now known to influence a number of physiological and pathological processes including angiogenesis and angiostasis (5).

- 57 -

IP-10 and MIG belong to a subset of the family of CXC chemokines (2) that bind the chemokine receptor CXCR3 (6). The CXC chemokine family can be further subdivided based on the presence or absence of a Glu-Leu-Arg or ELR motif at the NH₂ terminus of the chemokine. CXC chemokines that contain the ELR motif are potent promoters of angiogenesis whereas CXC chemokines that lack the ELR motif, as is the case for IP-10 and MIG, are potent inhibitors of angiogenesis (2).

2. Material and Methods

2.1. ODNs

10 ODN 1826 (TCCATGACGTTCTGACGTT; SEQ ID NO: 69)

2.2 *Matrigel® - (BD)*

Matrix solution is liquid at 4°C and solidifies at room temperature. When injected *in vivo* Matrigel solidifies to form a plug. Matrigel allows for the delivery of angiogenic promoters such as basic fibroblastic growth factor (bFGF) for the induction of angiogenesis. Plugs can 15 then be removed to evaluate the level of angiogenesis as identified by the concentration of hemoglobin present. This system can be used to evaluate the anti-angiogenic potential of different compounds.

2.3 *Hemoglobin quantification kit*

Drabkin method reagent kit (Sigma)

20 2.4 *Protein quantification*

Protein quantification kit (BioRad)

2.5 *Experimental design*

For each group of 5 mice, the Matrigel was prepared as follows:

Group 1 - Matrigel alone.

25 3.5 mL of Matrigel

500 µL/mouse was injected subcutaneously (SC) right of center of the abdomen

Group 2 - Matrigel + bFGF (150ng/mL) + heparin (40 units/mL)

52.5 µL bFGF (10µg/mL)

23.2 µL heparin (6039 units/mL)

30 3.42 mL Matrigel

500 µL/mouse was injected SC right of center of the abdomen

Group 3 - Matrigel + bFGF (150 ng/mL) + heparin (40 units/mL) + oligo 1826 (1mg/mL)

- 58 -

- 52.5 µL bFGF (10µg/mL)
23.2 µL heparin (6039 units/mL)
233 µL oligo 1826 (15mg/mL)
3.19 mL Matrigel
5 500µL/mouse was injected SC right of center of the abdomen
Group 4 - Matrigel + bFGF (150ng/mL) + heparin (40 units/mL)
52.5 µL bFGF (10µg/mL)
23.2 µL heparin (6039 units/mL)
3.42 mL Matrigel
10 500 µL/mouse was injected SC right of center of the abdomen
This group received daily SC injections, for 6 days, of 100 µL of ODN 1826 (1mg/mL) on the opposite flank from the Matrigel plug.
- 2.6 Determination of Hemoglobin and total protein content of Matrigel plugs**
On day 6 the animals were euthanised and the Matrigel plugs collected. The plugs were
15 placed in 0.3 mL of sterile PBS and placed at 4°C over night to allow the Matrigel to liquify.
The hemoglobin and total protein content of the Matrigel plugs was determined using the methods described above. The hemoglobin content of the Matrigel plugs was expressed as (mg/mL)/mg of total protein.
- 20 **3. Preliminary Results**
When angiogenic factors were added to the Matrigel (Group 2), there was a significant increase in the amount of hemoglobin present in the Matrigel plug at 6 days when compared to Matrigel alone (Group 1) ($p<0.05$). (See Figure 1.)
When CpG was included in the Matrigel plug along with the angiogenic factors
25 (Group 3), there was a greater than 2 fold decrease in the amount of hemoglobin present in the Matrigel plug at 6 days when compared to the Matrigel containing the angiogenic factors (Group 2). (See Figure 1.)
When CpG was administered daily by subcutaneous injection, rather than present in the Matrigel plug, to the mouse in the flank opposite to the Matrigel plug which contained
30 angiogenic factors (Group 4) there was no significant difference in the amount of hemoglobin present in the Matrigel plug at 6 days when compared to Matrigel containing the angiogenic factors (Group 2). (See Figure 1.)

- 59 -

These preliminary results suggest that the inclusion of CpG ODN directly within the Matrigel (Group 3) had a negative influence on angiogenesis. Although daily delivery of CpG to the opposite flank from the Matrigel plug did not appear to influence angiogenesis, it is possible that CpG administered intravenously or subcutaneously in a region closer to the 5 plug (and accordingly tumor mass) would manifest anti-angiogenic activity. CpG ODN may have to be present in the vicinity of active angiogenesis in order to have a negative influence.

4. References

1. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. *Nat Med.* 6: 389-95.
- 10 2. Belperio, J. A., et al. 2000. CXC chemokines in angiogenesis. *J Leukoc Biol.* 68: 1-8.
3. Carmeliet, P., R. K. Jain. 2000. Angiogenesis in cancer and other diseases. *Nature.* 407: 249-57.
4. Zetter, B. R. 1998. Angiogenesis and tumor metastasis. *Annu Rev Med.* 49: 407-24.
5. Rossi, D., A. Zlotnik. 2000. The biology of chemokines and their receptors. *Annu Rev 15 Immun.* 18: 217-42.
6. Loetscher, M., et al. 1996. Chemokine receptor specific for IP10 and MIG: structure, function, and expression in activated T-lymphocytes. *J Exp Med.* 184: 963-9.
7. Coughlin, C. M., et al. 1998. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. *Immunity.* 9: 25-34.
- 20 8. Strasly, M., et al. 2001. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. *J Immunol.* 166: 3890-9.
9. Kanegane, C., et al. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. *J Leukoc Biol.* 64: 384-92.

25

Equivalents

It should be understood that the preceding is merely a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. It is intended that the invention encompass all such modifications 30 within the scope of the appended claims. All references, patents and patent applications and publications that are cited or referred to in this application are incorporated in their entirety herein by reference.

- 60 -

I claim:

- 61 -

Claims

1. A method of inhibiting angiogenesis in a subject in need of such treatment comprising administering to the subject at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis in the subject.

5

2. The method of claim 1, wherein the at least one antiangiogenic nucleic acid molecule comprises at least one sequence set forth as SEQ ID NOs: 1-1093.

3. The method of claim 1, wherein two or more antiangiogenic nucleic acid molecules

10 are administered.

4. The method of claim 1, further comprising administering to the subject at least one non-nucleic acid angiogenesis inhibitor molecule.

15 5. The method of claim 1, wherein the angiogenesis is associated with a condition selected from the group consisting of a solid tumor growth, a tumor metastasis, and a precancerous lesion.

20 6. The method of claim 1, wherein the nucleic acid is a CpG nucleic acid having an unmethylated CpG motif.

7. The method of claim 1, wherein the nucleic acid is a T-rich nucleic acid.

8. The method of claim 1, wherein the nucleic acid is a poly G nucleic acid.

25

9. The method of claim 1, wherein the nucleic acid is isolated.

10. The method of claim 1, wherein the nucleic acid does not encode a protein having antiangiogenesis activity.

30

11. The method of claim 1, wherein the nucleic acid has a modified backbone.

- 62 -

12. The method of claim 11, wherein the modified backbone is a phosphate backbone modification.
13. The method of claim 11, wherein the modified backbone is a peptide modified oligonucleotide backbone.
5
14. The method of claim 1, further comprising administering to the subject at least one anticancer agent.
- 10 15. The method of claim 1, further comprising administering to the subject at least one antiarthritis agent.
16. The method of claim 6, wherein the CpG nucleic acid comprises:
5' X₁ X₂CGX₃ X₄ 3'
15 wherein C is unmethylated, and wherein X₁X₂ and X₃X₄ are nucleotides.
17. The method of claim 16, wherein the 5' X₁ X₂CGX₃ X₄ 3' sequence is a non-palindromic sequence.
- 20 18. The method of claim 16, wherein the CpG nucleic acid has 8 to 100 nucleotides.
19. The method of claim 16, wherein X₁X₂ are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X₃X₄ are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG,
25 TpC, ApC, CpC, TpA, ApA, and CpA.
20. The method of claim 16, wherein X₁X₂ are selected from the group consisting of GpA and GpT and X₃X₄ are TpT.
- 30 21. The method of claim 16, wherein X₁X₂ are both purines and X₃X₄ are both pyrimidines.
22. The method of claim 16, wherein X₂ is a T and X₃ is a pyrimidine.

- 63 -

23. The method of claim 16, wherein the CpG nucleic acid is 8 to 40 nucleotides in length.
24. The method of claim 16, wherein the CpG nucleic acid has a sequence selected from
5 the group consisting of SEQ ID NOS: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58,
64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-
150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-
240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-
307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369,
10 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-
443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488,
489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-
576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664,
15 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763,
766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818,
820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904,
and 909-913.
25. The method of claim 7, wherein the T-rich nucleic acid is a poly T nucleic acid
20 comprising
- 5' TTTT 3'.
26. The method of claim 25, wherein the poly T nucleic acid comprises
- 5' X₁ X₂TTTX₃ X₄ 3'
- 25 wherein X₁, X₂, X₃ and X₄ are nucleotides.
27. The method of claim 25, wherein the T rich nucleic acid comprises a plurality of poly
T nucleic acid motifs.
- 30 28. The method of claim 26, wherein X₁X₂ is TT.
29. The method of claim 26, wherein X₃X₄ is TT.

- 64 -

30. The method of claim 26, wherein X_1X_2 is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.
31. The method of claim 26, wherein X_3X_4 is selected from the group consisting of TA,
5 TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.
32. The method of claim 25, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 25% T.
- 10 33. The method of claim 7, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 25% T.
34. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 30% T.
- 15 35. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 50% T.
36. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide
20 composition of greater than 60% T.
37. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 80% T.
- 25 38. The method of claim 7, wherein the T rich nucleic acid comprises at least 20 nucleotides.
39. The method of claim 7, wherein the T rich nucleic acid comprises at least 24 nucleotides.
- 30 40. The method of claim 8, wherein the poly G nucleic acid comprises:
 $5' X_1X_2GGGX_3X_4 3'$
wherein X_1 , X_2 , X_3 , and X_4 are nucleotides.

- 65 -

41. The method of claim 40, wherein at least one of X₃ and X₄ are a G.
42. The method of claim 40, wherein both of X₃ and X₄ are a G.
5
43. The method of claim 8, wherein the poly G nucleic acid comprises the following formula:
$$5' \text{GGGNNGGG} 3'$$
wherein N represents between 0 and 20 nucleotides.
10
44. The method of claim 8, wherein the poly G nucleic acid comprises the following formula:
$$5' \text{GGGNNGGGNGGG} 3'$$
wherein N represents between 0 and 20 nucleotides.
15
45. The method of claim 8, wherein the poly G nucleic acid is free of unmethylated CG dinucleotides
20
46. The method of claim 45, wherein the poly G nucleic acid is selected from the group consisting of SEQ ID NOs: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938.
25
47. The method of claim 8, wherein the poly G nucleic acid includes at least one unmethylated CG dinucleotide.
30
48. The method of claim 47, wherein the poly G nucleic acid is selected from the group consisting of SEQ ID NOs: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.
49. The method of claim 1, wherein the nucleic acid is a synthetic nucleic acid.
35
50. The method of claim 9, wherein the nucleic acid is administered on a routine schedule.

- 66 -

51. The method of claim 1, wherein the angiogenesis is associated with a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars.
52. The method of claim 1, wherein the nucleic acid is not an antisense molecule.
- 10 53. A pharmaceutical composition comprising an amount of at least one antiangiogenic nucleic acid molecule effective to inhibit angiogenesis and a pharmaceutically acceptable carrier.
- 15 54. The pharmaceutical composition of claim 53, wherein the at least one antiangiogenic nucleic acid molecule comprises at least one sequence set forth as SEQ ID NOS: 1-1093.
55. The pharmaceutical composition of claim 53, wherein two or more antiangiogenic nucleic acid molecules are administered.
- 20 56. The pharmaceutical composition of claim 53, further comprising at least one non-nucleic acid angiogenesis inhibitor molecule.
57. The pharmaceutical composition of claim 53, wherein the antiangiogenic nucleic acid molecule has a modified backbone.
- 25 58. The pharmaceutical composition of claim 57, wherein the modified backbone is a phosphate modified backbone.
- 30 59. The pharmaceutical composition of claim 58, wherein the phosphate modified backbone is a phosphorothioate modified backbone.
60. The pharmaceutical composition of claim 53, further comprising an anticancer agent.

- 67 -

61. The pharmaceutical composition of claim 53, wherein the nucleic acid is a CpG nucleic acid.
- 5 62. The pharmaceutical composition of claim 53, wherein the nucleic acid is a T-rich nucleic acid.
63. The pharmaceutical composition of claim 53, wherein the nucleic acid is a poly G nucleic acid.
- 10 64. The pharmaceutical composition of claim 53, wherein the nucleic acid is isolated.
65. The pharmaceutical composition of claim 53, wherein the nucleic acid is not an antisense molecule.
- 15 66. A kit comprising
a first container housing at least one antiangiogenic nucleic acid molecule, and
instructions for administering the antiangiogenic nucleic acid to a subject having a condition characterized by unwanted angiogenesis.
- 20 67. The kit of claim 66, wherein the antiangiogenic nucleic acid has a modified backbone.
68. The kit of claim 67, wherein the modified backbone is a phosphate modified backbone.
- 25 69. The kit of claim 67, wherein the phosphate modified backbone is a phosphorothioate modified backbone.
70. The kit of claim 65, further comprising a second container housing at least one non-nucleic acid antiangiogenic agent.
- 30 71. The kit of claim 65, further comprising a second container housing at least one anticancer agent.

- 68 -

72. The kit of claim 69, further comprising a third container housing at least one anticancer agent.

5 73. The kit of claim 65, wherein the nucleic acid is not an antisense molecule.

74. The kit of claim 65, wherein the instructions relate to administering the antiangiogenic nucleic acid to a subject having a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration, 10 corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars.




Figure 1

- 1 -

SEQUENCE LISTING

<110> Coley Pharmaceutical Group, Inc.

<120> Inhibition of Angiogenesis by Nucleic Acids

<130> C1037/7025WO (HCL/MAT)

<150> US 60/255,534

<151> 2000-12-14

<160> 1093

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1

tctcccgccg tgccat

18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 2

ataatccagg ttgaaccaag

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 3

ataatcgacg ttcaagcaag

20

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 4

taccgcgtgc gaccctct

18

- 2 -

<210> 5
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 5
ggggaggg 9

<210> 6
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 6
ggggagggg 9

<210> 7
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 7
ggtgagg 9

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 8
tccatgtngt tcctgatgct 20

<210> 9
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (11)...(11)
<223> m5c

<223> Synthetic Sequence

- 3 -

<400> 9
gctacaccttag ngtga 15

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 10 20
tccatgangt tqctgatgct

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (13)...(13)
<223> m5c

<223> Synthetic Sequence

<400> 11 20
tccatgacgt tcntgatgct

<210> 12
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 12 15
gctagangtt agtgt

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 13 19
agctccatgg tgctcactg

<210> 14
<211> 20

- 4 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 14
ccacgtcgac cctcaggcga 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 15
gcacatcgac cccgagccga 20

<210> 16
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 16
gtcaactcgat gtacacctga 19

<210> 17
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 17
gttggataaca ggcgcgactt tggttg 25

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 18
gattcaactt ggcgcgtatct taggc 25

<210> 19
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 5 -

<400> 19
accatggacg aactgtttcc cctc 24

<210> 20
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 20
accatggacg agctgtttcc cctc 24

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 21
accatggacg acctgtttcc cctc 24

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 22
accatggacg tactgtttcc cctc 24

<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 23
accatggacg gtctgtttcc cctc 24

<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 24
accatggacg ttctgtttcc cctc 24

<210> 25
<211> 25
<212> DNA

- 6 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 25
ccactcacat ctgctgctcc acaag 25

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 26
acttctcata gtccccttgg tccag 25

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 27
tccatgagct tcctgagtc 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (9)...(9)
<223> I

<221> modified_base
<222> (11)...(11)
<223> I

<221> modified_base
<222> (15)...(15)
<223> I

<400> 28
gaggaaggng nggangacgt 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 7 -

<221> modified_base
<222> (7)...(7)
<223> I

<221> modified_base
<222> (13)...(13)
<223> I

<221> modified_base
<222> (18)...(18)
<223> I

<400> 29
gtgaatncgt tcncgggnct 20

<210> 30
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 30
aaaaaaa 6

<210> 31
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 31
ccccccc 6

<210> 32
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 32
ctgtca 6

<210> 33
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 33
tcgttag 6

<210> 34
<211> 6

- 8 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 34
tcgtgg 6

<210> 35
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 35
cgtcgt 6

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 36
tccatgtcgg tcctgagtct 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 37
tccatgccgg tcctgagtct 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 38
tccatgacgg tcctgagtct 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 9 -

<400> 39
tccatgacgg tcctgagtct 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 40
tccatgtcga tcctgagtct 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 41
tccatgtcgc tcctgagtct 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 42
tccatgtcggt tcctgagtct 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 43
tccatgacgt tcctgagtc 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 44
tccataaacgt tcctgagtc 20

<210> 45
<211> 20
<212> DNA

- 10 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 45
tccatgacgt ccctgagtct 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 46
tccatcacgt gcctgagtct 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 47
tccatgctgg tcctgagtct 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 48
tccatgtngg tcctgagtct 20

<210> 49
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 49
ccgcttcctc cagatgagct catgggttcc tccaccaag 39

<210> 50
<211> 39
<212> DNA
<213> Artificial Sequence

- 11 -

<220>
<223> Synthetic Sequence

<400> 50
cttggtgag aaacccatga gtcatctgg aggaagcgg 39

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 51
ccccaaaggg atgagaagtt 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 52
agatagcaaa tcggctgacg 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 53
ggttcacgtg ctcatggctg 20

<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 54
tctcccagcg tgcgccat 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 55
tctcccagcg tgcgccat 18

- 12 -

<210> 56
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 56 18
taccgcgtgc gaccctct

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 57 20
ataatccagc ttgaaccaag

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 58 20
ataatcgacg ttcaagcaag

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 59 20
tccatgattt tcctgatttt

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 60 24
ttgtttttt gtttttttgt tttt

<210> 61
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

- 13 -

<223> Synthetic Sequence

<400> 61
tttttttgtt ttttttgtt tt 22

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 62
tgctgctttt gtgctttgtt gctt 24

<210> 63
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 63
tgctgcttgtt gcttttgtc tt 22

<210> 64
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 64
gcattcatca ggcgggcaag aat 23

<210> 65
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 65
taccgagctt cgacgagatt tca 23

<210> 66
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 66
gcatgacgtt gagct 15

<210> 67

- 14 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 67
cacgttggagg ggcatt 15

<210> 68
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 68
ctgctgagac tggag 15

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 69
tccatgacgt tcctgacgtt 20

<210> 70
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 70
gcatgagctt gagctga 17

<210> 71
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 71
tcagcgtcgcc 12

<210> 72
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 15 -

<400> 72
atgacgttcc tgacgtt 17

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 73
ttttggggttt ttggggtttt 20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 74
tctaggcttt ttaggcttcc 20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 75
tgcatttttt aggccaccat 20

<210> 76
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 76
tctcccagcg tgcgtgcgcc at 22

<210> 77
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 77
tctcccagcg ggcgcat 17

<210> 78
<211> 18

- 16 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 78
tctcccaagcg agcgccat 18

<210> 79
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 79
tctcccaagcg cgcgccat 18

<210> 80
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 80
gggggtgacgt tcaggggggg 19

<210> 81
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 81
gggggtccagc gtgcgccatg gggg 24

<210> 82
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 82
gggggtgtcgt tcaggggggg 19

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 17 -

<400> 83
tccatgtcg tccatgtcgtt 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 84
tccatagcgt tcctagcgtt 20

<210> 85
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 85
tcgtcgctgt ctccgcttct t 21

<210> 86
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 86
gcatgacgtt gagct 15

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 87
tctcccagcg tgccatat 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<221> modified_base
<222> (17)...(17)
<223> m5c

- 18 -

<223> Synthetic Sequence

<400> 88
tccatgangt tcctgangtt 20

<210> 89
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 89
gcatgangtt gagct 15

<210> 90
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 90
tccagcgtgc gccata 16

<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 91
tctcccagcg tgcgccat 18

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 92
tccatgagct tcctgagtc 20

<210> 93
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 19 -

<400> 93
gcatgtcggtt gagct 15

<210> 94
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 94 19
tcctgacgtt cctgacgtt

<210> 95
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 95 15
gcatgatgtt gagct

<210> 96
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 96 15
gcatttcgag gagct

<210> 97
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 97 15
gcatgttagct gagct

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 98 20
tccaggacgt tcctagttct

<210> 99
<211> 20
<212> DNA

- 20 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 99
tccaggagct tcctagttct 20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 100
tccaggatgt tcctagttct 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 101
tccagtc tag gcctagttct 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 102
tccagttcga gcctagttct 20

<210> 103
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 103
gcatggcggt gagct 15

<210> 104
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 104

- 21 -

gcatagcggtt gagct 15
<210> 105
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 105
gcattgcgtt gagct 15
<210> 106
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 106
gcttgcgttg cgttt 15
<210> 107
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 107
tctcccaagcg ttgcgccata t 21
<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 108
tctcccaagcg tgcgttatat 20
<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 109
tctccctgcg tgcgccatat 20
<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 110
tctgcgtgcg tgcgccatat 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 111
tctcctagcg tgcgccatat 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 112
tctcccaagcg tgcgcctttt 20

<210> 113
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> misc_difference
<222> (5)...(5)
<223> n is a or g or c or t/u

<221> misc_difference
<222> (6)...(6)
<223> d is a or g or t/u; not c

<221> misc_difference
<222> (9)...(10)
<223> h is a or c or t/u; not g

<400> 113
gctandcghh agc 13

<210> 114
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 114

- 23 -

tcctgacgtt ccc 13
<210> 115
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 115
ggaagacgtt aga 13
<210> 116
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 116
tcctgacgtt aga 13
<210> 117
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 117
tcagaccaggc tggtcgggtg ttcctga 27
<210> 118
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 118
tcaggaacac ccgaccagct ggtctga 27
<210> 119
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 119
gcttagtcgat agc 13
<210> 120
<211> 13
<212> DNA
<213> Artificial Sequence

- 24 -

<220>
<223> Synthetic Sequence

<400> 120
gctagtcgct agc 13

<210> 121
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 121
gcttgacgtc tagc 14

<210> 122
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 122
gcttgacgtt tagc 14

<210> 123
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 123
gcttgacgtc aagc 14

<210> 124
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 124
gcttagacgtt tagc 14

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 125
tccatgacat tcctgatgct 20

- 25 -

<210> 126
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 126
gctagacgtc tagc 14

<210> 127
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 127
ggctatgtcg ttccctagcc 19

<210> 128
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 128
ggctatgtcg atcctagcc 19

<210> 129
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 129
ctcatgggtt tctccaccaa g 21

<210> 130
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 130
cttgggtggag aaacccatga g 21

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

- 26 -

<220>
<223> Synthetic Sequence

<400> 131
tccatgacgt tcctagttct 20

<210> 132
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 132
ccgcttcctc cagatgagct catg 24

<210> 133
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 133
catgagctca tctggaggaa gcgg 24

<210> 134
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 134
ccagatgagc tcatgggttt ctcc 24

<210> 135
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 135
ggagaaaaccc atgagctcat ctgg 24

<210> 136
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 136
agcatcagga acgacatgga 20

- 27 -

<210> 137
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 137
tccatgacgt tcctgacggtt 20

<210> 138
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 138
gcgcgcgcgc gcgcgcgc 19

<210> 139
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 139
ccggccggcc ggccggccgg 20

<210> 140
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 140
ttccaatcag cccccccccc tctggcccca ccctcaccct cca 43

<210> 141
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 141
tggagggtga gggggggcc agagcggtg gggctgattg gaa 43

<210> 142
<211> 27
<212> DNA
<213> Artificial Sequence

<220>

- 28 -

<223> Synthetic Sequence

<400> 142
tcaaatgtgg gattttccca tgagtct 27

<210> 143
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 143
agactcatgg gaaaatccca catttga 27

<210> 144
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 144
tgccaagtgc tgagtcacta ataaaga 27

<210> 145
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 145
tctttatttag tgactcagca ctggca 27

<210> 146
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 146
tgcaggaagt ccgggttttc cccaaacccc c 31

<210> 147
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 147
gggggggttgg ggaaaacccg gacttcctgc a 31

<210> 148

- 29 -

<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 148
ggggactttc cgctggggac tttccagggg gactttcc 38

<210> 149
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 149
tccatgacgt tcctctccat gacgttcctc tccatgacgt tcctc 45

<210> 150
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 150
gaggaacgtc atggagagga acgtcatgga gaggaacgtc atgga 45

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 151
ataatagagc ttcaagcaag 20

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 152
tccatgacgt tcctgacgtt 20

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 30 -

<400> 153
tccatgacgt tcctgacgtt 20

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 154
tccaggactt tcctcaggtt 20

<210> 155
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 155
tcttgcgatg ctaaaggacg tcacattgca caatcttaat aaggt 45

<210> 156
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 156
accttattaa gattgtgcaa tgtgacgtcc ttttagcatcg caaga 45

<210> 157
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 157
tcctgacgtt cctggcggtc ctgtcgct 28

<210> 158
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 158
tcctgtcgct cctgtcgct 19

<210> 159
<211> 15

- 31 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 159
tcctgacgtt gaagt 15

<210> 160
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 160
tcctgtcggtt gaagt 15

<210> 161
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 161
tcctggcggtt gaagt 15

<210> 162
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 162
tcctgccgtt gaagt 15

<210> 163
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 163
tccttacgtt gaagt 15

<210> 164
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 32 -

<400> 164
tccttaacgtt gaagt 15

<210> 165
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 165
tcctcacgtt gaagt 15

<210> 166
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 166
tcctgacgat gaagt 15

<210> 167
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 167
tcctgacgct gaagt 15

<210> 168
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 168
tcctgacgggt gaagt 15

<210> 169
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 169
tcctgacgta gaagt 15

<210> 170
<211> 15
<212> DNA

- 33 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 170
tcctgacgtc gaagt 15

<210> 171
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 171
tcctgacgtg gaagt 15

<210> 172
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 172
tcctgagctt gaagt 15

<210> 173
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 173
gggggacgtt ggggg 15

<210> 174
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 174
tcctgacgtt ctttc 15

<210> 175
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 175

- 34 -

tctcccagcg agcgagcgcc at	22
<210> 176	
<211> 32	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 176	
tcctgacgtt cccctggcgg tccccctgtcg ct	32
<210> 177	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 177	
tcctgtcgct cctgtcgctc ctgtcgct	28
<210> 178	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 178	
tcctggcgaaat gaagt	15
<210> 179	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> modified_base	
<222> (7)...(7)	
<223> m5c	
<223> Synthetic Sequence	
<400> 179	
tcctgangtt gaagt	15
<210> 180	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> modified_base	
<222> (3)...(3)	
<223> m5c	
<223> Synthetic Sequence	

- 35 -

<400> 180 tcntgacgtt gaagt	15
<210> 181 <211> 15 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 181 tccttagcgtt gaagt	15
<210> 182 <211> 15 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 182 tccagacgtt gaagt	15
<210> 183 <211> 15 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 183 tcctgacggg gaagt	15
<210> 184 <211> 15 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 184 tcctggcggt gaagt	15
<210> 185 <211> 27 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 185 ggctccgggg agggaaatttt tgtctat	27
<210> 186 <211> 27	

- 36 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 186
atagacaaaa attccctccc cggagcc 27

<210> 187
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 187
tccatgagct tccttgagtc t 21

<210> 188
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 188
tcgtcgctgt ctccgcttct t 21

<210> 189
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 189
tcgtcgctgt ctccgcttct t 21

<210> 190
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 190
tcgagacatt gcacaatcat ctg 23

<210> 191
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 37 -

<400> 191
cagattgtgc aatgtctcga

<210> 192
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 192
tccatgtcgt tcctgatgcg

<210> 193
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 193
gcgatgtcgt tcctgatgct

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 194
gcgatgtcgt tcctgatgcg

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 195
tccatgtcgt tccgcgcgcg

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 196
tccatgtcgt tcctgccgt

<210> 197
<211> 20
<212> DNA

- 38 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 197
tccatgtcgt tcctgttagct 20

<210> 198
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 198
gcggcgcccc gcgcgccccc 20

<210> 199
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 199
atcaggaacg tcatggaaag c 21

<210> 200
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 200
tccatgagct tcctgagtct 20

<210> 201
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 201
tcaaacgtt 8

<210> 202
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 202

- 39 -

8

tcaagctt <210> 203
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 203
tcctgtcggtt cctgtcggtt 19

<210> 204
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 204
tccatgtcgt ttttgtcggtt 20

<210> 205
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 205
tcctgtcggtt ctttgtcggtt 20

<210> 206
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 206
tccttgtcgt tcctgtcggtt 20

<210> 207
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 207
tccattccat gacgttcctg atgcttcca 29

- 40 -

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 208
tcctgtcggtt ttttgtcggtt 20

<210> 209
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 209
tcgtcgcgtgt ctccgcgttct t 21

<210> 210
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 210
tcgtcgcgtgt ctgccgttct t 21

<210> 211
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 211
tcgtcgcgtgt tgtcggttct t 21

<210> 212
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 212
tcctgtcggtt cctgtcggttg gaacgacagg 30

<210> 213
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

- 41 -

<223> Synthetic Sequence

<400> 213
tcctgtcggtt cctgtcggtt caacgtcagg aacgacagga 40

<210> 214
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 214
ggggtctgtc gttttggggg g 21

<210> 215
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 215
ggggtctgtg cttttggggg g 21

<210> 216
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 216
tccggccgtt gaagt 15

<210> 217
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 217
tccggacggt gaagt 15

<210> 218
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 218
tccccgccgtt gaagt 15

<210> 219

R3
- 42 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 219
tccagacggt gaagt 15

<210> 220
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 220
tcccgacggt gaagt 15

<210> 221
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 221
tccagagctt gaagt 15

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<221> modified_base
<222> (17)...(17)
<223> m5c

<223> Synthetic Sequence

<400> 222
tccatgtngt tcctgtngtt 20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 223
tccatgacgt tcctgacggt 20

- 43 -

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 224
ggggttgacg ttttgggggg 20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 225
tccaggactt ctctcaggtt 20

<210> 226
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 226
tttttttttt tttttttttt 20

<210> 227
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 227
tccatgccgt tcctgccgtt 20

<210> 228
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 228
tccatggcgg gcctggcggg 20

<210> 229
<211> 20
<212> DNA
<213> Artificial Sequence

- 44 -

<220>
<223> Synthetic Sequence

<400> 229
tccatgacgt tcctgccgtt 20

<210> 230
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 230
tccatgacgt tcctggcggg 20

<210> 231
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 231
tccatgacgt tcctgcgttt 20

<210> 232
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 232
tccatgacgg tcctgacgg 20

<210> 233
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 233
tccatgcgtg cgtgcgttt 20

<210> 234
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 234
tccatgcgtt gcgttgcgtt 20

- 45 -

<210> 235
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 235
tccattccat tctaggcctg agtcttccat 30

<210> 236
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 236
tccatagcgt tcctagcgtt 20

<210> 237
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 237
tccatgtcgt tcctgtcggt 20

<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 238
tccatagcga tcctagcgat 20

<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 239
tccattgcgt tccttgcggt 20

<210> 240
<211> 20

- 46 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 240
tccatagcgg tccttagcggt 20

<210> 241
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 241
tccatgattt tcctgcagg t cctgatttt 29

<210> 242
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 242
tccatgacgt tcctgcagg t cctgacggt 29

<210> 243
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 243
ggcggcggcgcg gcggcggcgg 20

<210> 244
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 244
tccacgacgt tttcgacgtt 20

<210> 245
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 47 -

<400> 245
tcgtcggtt cgttgcgtt 20

<210> 246
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 246
tcgtcggtttt gtcgttttgtt cgtt 24

<210> 247
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 247
tcgtcggtt cgttttgtcg tt 22

<210> 248
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 248
gcgtgcgttg tcgttgcgt t 21

<210> 249
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (6)...(6)
<223> m5c

<221> modified_base
<222> (10)...(10)
<223> m5c

<221> modified_base
<222> (15)...(15)
<223> m5c

<400> 249

- 48 -

cnggcnggcn gggcnccgg 19
<210> 250
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 250 20
gcggcgggcg gcgcgcgc
<210> 251
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (3)...(3)
<223> I

<221> modified_base
<222> (8)...(8)
<223> I

<221> modified_base
<222> (14)...(14)
<223> I

<400> 251
agncccgnga acgnattcac 20
<210> 252
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 252
tgtcgttgt cgtttgcgt t 21
<210> 253
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 253
tgtcgttgtc gttgtcggtg tcgtt 25
<210> 254
<211> 25
<212> DNA

- 49 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 254
tgtcgttgtc gttgtcggtt tcgtt 25

<210> 255
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 255
tcgtcgctgt cgtt 14

<210> 256
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 256
tgtcgttgtc gtt 13

<210> 257
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 257
cccccccccc ccccccccccc 20

<210> 258
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 258
tctagcgttt tttagcgttcc 20

<210> 259
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 259

- 50 -

tgcatccccc aggccaccat 20
<210> 260
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 260
tcgtcgtcgt cgtcgtcg tc gtt 23

<210> 261
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 261
tcgtcgttgt cgttgtcgtt 20

<210> 262
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 262
tcgtcgttt gtgcgttgtt cgtt 24

<210> 263
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 263
tcgtcgttgt cgtttgtcgt tt 22

<210> 264
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 264
ggggaggaggag gaacttctta aaattcccc agaatgttt 39

<210> 265
<211> 39
<212> DNA
<213> Artificial Sequence

- 51 -

<220>
<223> Synthetic Sequence

<400> 265
aaacattctg ggggaatttt aagaagttcc tccctcccc 39

<210> 266
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 266
atgtttaactt cttaaaattc ccccagaatg ttt 33

<210> 267
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 267
aaacattctg ggggaatttt aagaagtaaa cat 33

<210> 268
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 268
atgtttaacta gacaaaattc ccccagaatg ttt 33

<210> 269
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 269
aaacattctg ggggaatttt gtcttagtaaa cat 33

<210> 270
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 270
aaaattgacg ttttaaaaaaa 20

- 52 -

<210> 271
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 271
cccccttgacg ttttcccccc 20

<210> 272
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 272
ttttcggttgt ttttgcgtt 20

<210> 273
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 273
tcgtcggttt gtcgttttgt cgtt 24

<210> 274
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 274
ctgcagcctg ggac 14

<210> 275
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 275
accggtcgtta attatagtaa aaccc 25

<210> 276
<211> 21
<212> DNA
<213> Artificial Sequence

- 53 -

<220>
<223> Synthetic Sequence

<400> 276
ggtacactgtg gggacattgt g 21

<210> 277
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 277
agcaccgaac gtgagagg 18

<210> 278
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 278
tccatgccgt tcctgccgtt 20

<210> 279
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 279
tccatgacgg tcctgacgg 20

<210> 280
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 280
tccatgccgg tcctgccgg 20

<210> 281
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 281
tccatgcgcg tcctgcgcgt 20

- 54 -

<210> 282
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 282
ctggctttc tggttttttt ctgg 24

<210> 283
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 283
tcaggggtgg ggggaacctt 20

<210> 284
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 284
tccatgangt tcctagttct 20

<210> 285
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 285
tccatgatgt tcctagttct 20

<210> 286
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 286
cccgaaagtca ttccctctta acctgg 26

<210> 287
<211> 26

- 55 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 287
ccaggttaag aggaaatgac ttcggg 26

<210> 288
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 288
tcctggnggg gaaqt 15

<210> 289
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (5)...(5)
<223> m5c

<221> modified_base
<222> (9)...(9)
<223> m5c

<221> modified_base
<222> (12)...(12)
<223> m5c

<221> modified_base
<222> (14)...(14)
<223> m5c

<221> modified_base
<222> (16)...(16)
<223> m5c

<223> Synthetic Sequence

<400> 289
gnggnngng gngngngccc 20

<210> 290
<211> 20

- 56 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 290
tccatgtgct tcctgatgct 20

<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 291
tccatgtcct tcctgatgct 20

<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 292
tccatgtcgt tcctagttct 20

<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 293
tccaagttagt tcctagttct 20

<210> 294
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 294
tccatgttagt tcctagttct 20

<210> 295
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 57 -

<400> 295
tccccgcgt tccgcgcgtt 20

<210> 296
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 296
tcctggcggt octggcggtt 20

<210> 297
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 297
tcctggaggg gaagt 15

<210> 298
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 298
tcctgggggg gaagt 15

<210> 299
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 299
tcctggtgtgg gaagt 15

<210> 300
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 300
tcgtcgttt gtcgtttgt cgtt 24

<210> 301
<211> 24
<212> DNA

- 58 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 301
ctggtctttc tggttttttt ctgg 24

<210> 302
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 302
tccatgacgt tcctgacgtt 20

<210> 303
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 303
tccaggactt ctctcaggtt 20

<210> 304
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (5)...(5)
<223> m5c

<221> modified_base
<222> (13)...(13)
<223> m5c

<221> modified_base
<222> (21)...(21)
<223> m5c

<400> 304
tnngtngttt gtngtttg tngt 24

<210> 305
<211> 29
<212> DNA
<213> Artificial Sequence

- 59 -

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 305
tcgtcgaaaa gtcgttttgt cgaaaaaaa 29

<210> 306
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 306
gctatgacgt tccaaagg 18

<210> 307
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 307
tcaaacgtt 8

<210> 308
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 308
tccaggactt tcctcagg 20

<210> 309
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 309
ctctatgttag gccccgttgg 20

<210> 310
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 60 -

<223> Synthetic Sequence

<400> 310
ctttccgttg gaccctggg 20

<210> 311
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 311
gtccgggcca gcccaaagtc 20

<210> 312
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 312
gtgcgcgcga gcccgaaatc 20

<210> 313
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> I

<221> modified_base
<222> (17)...(17)
<223> I

<223> Synthetic Sequence

<400> 313
tccatgangt tcctgangtt 20

<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 314
aatagtgcgc ataacaaaac 20

<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence

- 61 -

<220>
<223> Synthetic Sequence

<400> 315
aatagtcgcc atggcgggc 20

<210> 316
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 316
tttttccatg tcgttcctga tgctttt 28

<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 317
tcctgtcggtt gaagttttt 20

<210> 318
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 318
gcttagctta gagcttttaga gctt 24

<210> 319
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 319
tgctgcttcc cccccccccc 20

<210> 320
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 62 -

<223> Synthetic Sequence

<400> 320
tcgacgttcc cccccccccc 20

<210> 321
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 321
tcgtcggttcc cccccccccc 20

<210> 322
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 322
tcgtcggttcc cccccccccc 20

<210> 323
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 323
tcggccgttcc cccccccccc 20

<210> 324
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 324
tcgtcgatcc cccccccccc 20

<210> 325
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 325
tcctgacgtt gaagt 15

<210> 326

- 63 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 326
tcctgccgtt gaagt 15

<210> 327
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 327
tcctgacgggt gaagt 15

<210> 328
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 328
tcctgagctt gaagt 15

<210> 329
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 329
tcctggcgaaa gaagt 15

<210> 330
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 330
aaaatctgtc cttttaaaaa a 21

<210> 331
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 64 -

<400> 331
gatccagtca cagtgacctg gcagaatctg gat 33

<210> 332
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 332
gatccagatt ctgccaggc actgtgactg gat 33

<210> 333
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 333
gatccagtca cagtgactca gcagaatctg gat 33

<210> 334
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 334
gatccagatt ctgctgagtc actgtgactg gat 33

<210> 335
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (16)...(16)
<223> m5c

<223> Synthetic Sequence

<400> 335
tcgtcgttcc ccccccncccc 20

<210> 336
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

- 65 -

<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 336
tngtngttcc cccccccccc 20

<210> 337
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 337
tngtcgttcc cccccccccc 20

<210> 338
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 338
tcgtngttcc cccccccccc 20

<210> 339
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 339
tcgtcgctcc cccccccccc 20

<210> 340
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 340
tcgtcggtcc cccccccccc 20

- 66 -

<210> 341
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 341
tcggcggtcc cccccccccc 20

<210> 342
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 342
ggcctttcc cccccccccc 20

<210> 343
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 343
tcgtcggtt gacgaaaaaa 24

<210> 344
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 344
tcgtcggtt gacgaaaaaa 24

<210> 345
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 345
ccgtcggtcc cccccccccc 20

<210> 346
<211> 20
<212> DNA
<213> Artificial Sequence

- 67 -

<220>
<223> Synthetic Sequence

<400> 346
gcgtcggttcc cccccccccc 20

<210> 347
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 347
tcgtcattcc cccccccccc 20

<210> 348
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 348
acgtcggttcc cccccccccc 20

<210> 349
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 349
ctgtcggttcc cccccccccc 20

<210> 350
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 350
tttttcgtcg ttccccccccc cccc 24

<210> 351
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature

- 68 -

<222> (18)...(20)
<223> Biotin moiety attached at 3' end of sequence.

<223> Synthetic Sequence

<400> 351
tcgtcggttcc cccccccccc 20

<210> 352
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (22)...(24)
<223> Biotin moiety attached at 3' end of sequence.

<223> Synthetic Sequence

<400> 352
tcgtcggtttt gtcgttttgt cgtt 24

<210> 353
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 353
tccagttccct tcctcagtct 20

<210> 354
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 354
tngtcggtttt gtcgttttgt cgtt 24

<210> 355
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 355
tcctggagggaatg 15

<210> 356

- 69 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 356
tcctgaaaag gaagt 15

<210> 357
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 357
tcgtcggtcc ccccccc 17

<210> 358
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (5)...(5)
<223> m5c

<221> modified_base
<222> (13)...(13)
<223> m5c

<221> modified_base
<222> (21)...(21)
<223> m5c

<400> 358
tngtngttt gtngtttgt ngtt 24

<210> 359
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 359
gggggtcaagc ttgaggggg 20

<210> 360
<211> 20

- 70 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 360
tgctgttcc cccccccccc 20

<210> 361
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 361
tcgtcgtcggt cgtt 14

<210> 362
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 362
tcgtcgtcggt cgtt 14

<210> 363
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 363
tcgtcgtcggt cgtt 14

<210> 364
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 364
tcaacgttga 10

<210> 365
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 71 -

<400> 365
tcaaacgtt 8
<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 366
atagtttcc atttttttac 20
<210> 367
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 367
aatagtgcgcc atcgcgcgac 20
<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 368
aatagtgcgcc atcccgggac 20
<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 369
aatagtgcgcc atccccccccc 20
<210> 370
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 370
tgctgctttt gtgcttttgt gctt 24
<210> 371
<211> 24
<212> DNA

- 72 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 371
ctgtgctttc tgtgttttc tgtg 24

<210> 372
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 372
ctaatttttc taattttttt ctaa 24

<210> 373
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 373
tcgtcggttgg tgcgttggt gtcgtt 26

<210> 374
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 374
tcgtcggttgg ttgtcggttt ggtt 24

<210> 375
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 375
accatggacg agctgttcc cctc 24

<210> 376
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 376

- 73 -

tcgtcgttt gcgtgcgttt 20
<210> 377
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 377
ctgtaagtga gcttggagag 20
<210> 378
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 378
gagaacgctg gacattcc 18
<210> 379
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 379
cggccgactc agtctatcg 20
<210> 380
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 380
gttctcagat aaagcggAAC cagcaacaga cacagaa 37
<210> 381
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 381
ttctgtgtct gttgctggtt ccgctttatc tgagaac 37
<210> 382
<211> 23
<212> DNA
<213> Artificial Sequence

- 74 -

<220>
<223> Synthetic Sequence

<400> 382
cagacacaga agcccgatag acg 23

<210> 383
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 383
agacagacac gaaacgacccg 20

<210> 384
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 384
gtctgtccca tgatctcgaa 20

<210> 385
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 385
gctggccagc ttacctcccg 20

<210> 386
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 386
ggggcctcta tacaacctgg g 21

<210> 387
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 387
ggggtccctg agactgcc 18

- 75 -

<210> 388
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 388
gagaacgctg gaccttccat 20

<210> 389
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 389
tccatgtcgg tcctgatgct 20

<210> 390
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 390
ctcttgcgac ctggaaggta 20

<210> 391
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 391
aggtacagcc aggactacga 20

<210> 392
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 392
accatggacg acctgtttcc cctc 24

<210> 393
<211> 24
<212> DNA
<213> Artificial Sequence

- 76 -

<220>
<223> Synthetic Sequence

<400> 393
accatggatt accttttcc cctt 24

<210> 394
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 394
atggaaggc cagcggttc 20

<210> 395
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 395
agcatcagga ccgacatgga 20

<210> 396
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 396
ctctccaaggc tcacttacag 20

<210> 397
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 397
tccctgagac tgccccaccc t 21

<210> 398
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 398
gccaccaaaa cttgtccatg 20

- 77 -

<210> 399
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 399
gtccatggcg tgcgggatga 20

<210> 400
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 400
cctctataca acctggac 19

<210> 401
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 401
cgggcgactc agtctatcg 20

<210> 402
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 402
gcgctaccgg tagcctgagt 20

<210> 403
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 403
cgactgccga acaggatatac ggtgatcagc actgg 35

<210> 404
<211> 35
<212> DNA
<213> Artificial Sequence

<220>

- 78 -

<223> Synthetic Sequence

<400> 404
ccagtgcgtga tcaccgatat cctgttcggc agtgc 35

<210> 405
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 405
ccaggttgta tagaggc 17

<210> 406
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 406
tctcccaagcg tacgccccat 18

<210> 407
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 407
tctcccaagcg tgcgtttt 18

<210> 408
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 408
tctcccgacg tgcgccccat 18

<210> 409
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 409
tctcccggtcg tgcgccccat 18

<210> 410

- 79 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 410
ataatcgctcg ttcaaggcaag 20

<210> 411
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 411
tcgtcgaaaa gtcgaaaaat cgt 23

<210> 412
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 412
tcgtcgaaaa gtcgaaaaat cgta 24

<210> 413
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 413
tcgtcgaaaa gtcgaaaaat cgta 24

<210> 414
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (3)...(3)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (8)...(8)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (11)...(11)
<223> n is a or c or g or t/u

- 80 -

<221> misc_difference
<222> (16)...(16)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (19)...(19)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (24)...(24)
<223> n is a or c or g or t/u

<223> Synthetic Sequence

<400> 414
tcntcgtntt ntcgtnttnt cgtn 24

<210> 415
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 415
tctcccaagcg tcgccccat 17

<210> 416
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 416
tctcccatcg tcgccccat 17

<210> 417
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 417
ataatcgtgc gttcaagaaaa g 21

<210> 418
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 418
ataatcgacg ttccccccccc 20

- 81 -

<210> 419
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 419
tctatcgacg ttcaagcaag 20

<210> 420
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 420
tcctgacggg gagt 14

<210> 421
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 421
tccatgacgt tcctgatcc 19

<210> 422
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 422
tccatgacgt tcctgatcc 19

<210> 423
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 423
tccatgacgt tcctgatcc 19

<210> 424
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

- 82 -

<223> Synthetic Sequence

<400> 424
tcctggcgtg gaagt 15

<210> 425
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 425
tccatgacgt tcctgatcc 19

<210> 426
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 426
tcgtcgctgt tgcgtttct t 21

<210> 427
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 427
agcagctta gagctttaga gctt 24

<210> 428
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 428
cccccccccc cccccccccc cccc 24

<210> 429
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 429
tcgtcgttt gtgttttgtt cgttttgtcg tt 32

<210> 430

- 83 -

<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 430
tcgtcgaaaa ttgtcgaaaa ttgtcgaa 28

<210> 431
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 431
tcgtcgaaaa tttttttttt 20

<210> 432
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 432
tttttcaacg ttgatttttt 20

<210> 433
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 433
ttttttttttt tttttttttt tttt 24

<210> 434
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 434
gggggtcgatcg ttttgggggg 20

<210> 435
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 84 -

<400> 435	
tcgtcgttt gtcgtttgg gggg	24
<210> 436	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 436	
tcgtcgctgt ctccgcttct tcttgcc	27
<210> 437	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 437	
tcgtcgctgt ctccg	15
<210> 438	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 438	
ctgtaagtga gcttggagag	20
<210> 439	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 439	
gagaacgctg gacattccat	20
<210> 440	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 440	
ccaggttgta tagaggc	17
<210> 441	
<211> 17	

- 85 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 441
gctagacgtt agcgtga 17

<210> 442
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 442
ggagctcttc gaacgccata 20

<210> 443
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 443
tctccatgat ggtttatcg 20

<210> 444
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 444
aagggtgggc agtctcaggg a 21

<210> 445
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 445
atcgaggac tggcgcgccg 20

<210> 446
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 86 -

<400> 446
ttaggacaag gtcttagggtg 20

<210> 447
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 447
accacacaacga gaggaacgcga 20

<210> 448
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 448
ggcagtgcag gctcacccggg 20

<210> 449
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 449
gaaccttcca tgctgtt 17

<210> 450
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 450
gctagacgtt agcgtga 17

<210> 451
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 451
gcttggaggg cctgtaagtg 20

<210> 452
<211> 12
<212> DNA

- 87 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 452
gtagccttcc ta 12

<210> 453
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 453
cggttagcctt ccta 14

<210> 454
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 454
cacggtagcc ttccta 16

<210> 455
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 455
agcacggtag cttccta 18

<210> 456
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 456
gaacgctgga cttccat 18

<210> 457
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 457

- 88 -

gaccttccat 10
<210> 458
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 458
tggaccttcc at 12
<210> 459
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 459
gctggacctt ccat 14
<210> 460
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 460
acgctggacc ttccat 16
<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 461
taagctctgt caacgccagg 20
<210> 462
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 462
gagaacgctg gacccat gt 22
<210> 463
<211> 20
<212> DNA
<213> Artificial Sequence

- 89 -

<220>
<223> Synthetic Sequence

<400> 463
tccatgtcgg tcctgatgct 20

<210> 464
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 464
ttcatgcctt gcaaaatggc g 21

<210> 465
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 465
tgcttagctgt gcctgtacct 20

<210> 466
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 466
agcatcagga ccgacatgga 20

<210> 467
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 467
gaccttccat gtcggtcctg at 22

<210> 468
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 468
acaaccacga gaacggaaac 20

- 90 -

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 469
gaaccttcca tgctgttccg 20

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 470
caatcaatct gaggagaccc 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 471
tcagctctgg tacttttca 20

<210> 472
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 472
tggttacggt ctgtcccatg 20

<210> 473
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 473
gtctatcgga ggactggcgc 20

<210> 474
<211> 20
<212> DNA
<213> Artificial Sequence

- 91 -

<220>
<223> Synthetic Sequence

<400> 474
cattttacgg gcgggcgggc 20

<210> 475
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 475
gaggggacca ttttacgggc 20

<210> 476
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 476
tgtccagccg aggggaccat 20

<210> 477
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 477
cgggcttacg gcggatgctg 20

<210> 478
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 478
tggacacctt atgtcggtcc 20

<210> 479
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 479
tgtcccatgt ttttagaagc 20

- 92 -

<210> 480
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 480
gtggttacgg tcgtgccccat 20

<210> 481
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 481
cctccaaatg aaagacccccc 20

<210> 482
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 482
ttgtactctc catgatggtt 20

<210> 483
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 483
ttccatgctg ttccggctgg 20

<210> 484
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 484
gaccttctat gtcggtcctg 20

<210> 485
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 93 -

<223> Synthetic Sequence
<400> 485
gagaccgctc gacattcgat 20
<210> 486
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 486
ttgccccata ttttagaaac 20
<210> 487
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 487
ttgaaaactga ggtgggac 18
<210> 488
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 488
ctatcgagg actggcgcbc c 21
<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 489
cttggagggc ctcccgccgg 20
<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 490
gctgaacctt ccatgctgtt 20
<210> 491

- 94 -

<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 491
tagaaacacgc atttttcttt tagggcagca ca 32

<210> 492
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 492
agatggttct cagataaagc ggaa 24

<210> 493
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 493
ttcccgctta tctgagaacc atct 24

<210> 494
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 494
gtcccagggtt gtatagaggc tgc 23

<210> 495
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 495
gcgccagtc tccgatagac 20

<210> 496
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 95 -

<400> 496
atcgaggac tggcgcgccg 20

<210> 497
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 497
ggtctgtccc atatttttag 20

<210> 498
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 498
tttttcaacg ttgaggggg 20

<210> 499
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 499
tttttcaagc gttgattttt t 21

<210> 500
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 500
ggggtcaacg ttgattttt 20

<210> 501
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 501
ggggtttca acgttttgag ggggg 25

<210> 502
<211> 20

- 96 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 502
ggttacggtc tgtcccatat 20

<210> 503
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 503
ctgtccata ttttagaca 20

<210> 504
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 504
accatcctga ggccattcgg 20

<210> 505
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 505
cgtctatcg gcttctgtgt ctg 23

<210> 506
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 506
ggccatccca cattgaaagt t 21

<210> 507
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 97 -

<400> 507
ccaaatatcg gtggtaaagc ac 22
<210> 508
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 508
gtgcttgacc accgatattt gg 22
<210> 509
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 509
gtgctgatca ccgatatacct gttcgg 26
<210> 510
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 510
ggccaacttt caatgtggga tggcctc 27
<210> 511
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 511
ttccggccgaa tggcctcagg atggtag 27
<210> 512
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 512
tatagtccct gagactgcc caccctctca acaacc 36
<210> 513
<211> 27
<212> DNA

- 98 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 513
gcagccctcta tacaacacctgg gacggga 27

<210> 514
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 514
ctatcgagg actggcgcg c 22

<210> 515
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 515
tatcgagg ctggcgccg g 21

<210> 516
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 516
gatcgagg ctggcgccg g 21

<210> 517
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 517
ccgaacagga tatcggtgat cagcac 26

<210> 518
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 518

- 99 -

ttttgggtc aacgttgggg gggg 24
<210> 519
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 519
ggggtcaacg ttgagggggg 20
<210> 520
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 520
cgcgcgcg cgcgcgcg 20
<210> 521
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 521
ggggcatgac gttcgaaaaaa 20
<210> 522
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 522
ggggcatgac gttcaaaaaa 20
<210> 523
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 523
ggggcatgag cttcgggggg 20
<210> 524
<211> 20
<212> DNA
<213> Artificial Sequence

- 100 -

<220>
<223> Synthetic Sequence

<400> 524
ggggcatgac gttcgaaaaaa 20

<210> 525
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 525
aaaacatgac gttcaaaaaaa 20

<210> 526
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 526
aaaacatgac gttcgaaaaaa 20

<210> 527
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 527
ggggcatgac gttcaaaaaaa 20

<210> 528
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 528
accatggacg atctgtttcc cctc 24

<210> 529
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 529
gccatggacg aactgttccc cctc 24

- 101 -

<210> 530
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 530
cccccccccc cccccccccc 20

<210> 531
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 531
gggggggggg gggggggggg 20

<210> 532
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 532
gctgtaaaaat gaatcgccg 20

<210> 533
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 533
ttcgggcgga ctcctccatt 20

<210> 534
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 534
tatgccgcgc ccggacttat 20

<210> 535
<211> 20
<212> DNA
<213> Artificial Sequence

- 102 -

<220>
<223> Synthetic Sequence

<400> 535
ggggtaatcg atcagggggg 20

<210> 536
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 536
tttgagaacg ctggaccc 20

<210> 537
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 537
gatcgctgat ctaatgctcg 20

<210> 538
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 538
gtcggtcctg atgctgttcc 20

<210> 539
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 539
tcgtcgtag ttcgctgtcg 20

<210> 540
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 540
ctggaccc 18

ctggacccatgcgg

- 103 -

<210> 541
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 541
gctcgttcag cgcggtct 17

<210> 542
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 542
ctggacaccttc catgtc 16

<210> 543
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 543
cactgtccattt cgtcga 16

<210> 544
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 544
cgctggacct tccatgtcgg 20

<210> 545
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 545
gctgagactca tgccgtctgc 20

<210> 546
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 104 -

<223> Synthetic Sequence

<400> 546
aacgctggac cttccatgtc 20

<210> 547
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 547
tgcatgccgt acacagctct 20

<210> 548
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 548
ccttccatgt cggtcctgat 20

<210> 549
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 549
tactcttcgg atcccttgcg 20

<210> 550
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 550
ttccatgtcg gtcctgat 18

<210> 551
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 551
ctgattgctc tctcgtga 18

<210> 552

- 105 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 552
ggcgtttattc ctgactcgcc 20

<210> 553
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 553
cctacgttgt atgcgcccag ct 22

<210> 554
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 554
ggggtaatcg atgagggggg 20

<210> 555
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 555
ttcgggcgga ctcctccatt 20

<210> 556
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 556
tttttttttt tttttttttt 20

<210> 557
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 106 -

<400> 557	
gggggtttttt tttttggggg	20
<210> 558	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 558	
tttttggggg ggggggtttt	20
<210> 559	
<211> 19	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 559	
gggggggggggg gggggggggt	19
<210> 560	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 560	
aaaaaaaaaaaa aaaaaaaaaaaa	20
<210> 561	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 561	
cccccaaaaa aaaaaccccc	20
<210> 562	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 562	
aaaaacccccc ccccaaaaaa	20
<210> 563	
<211> 27	

- 107 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 563
tttgaattca ggactggta ggttgag 27

<210> 564
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 564
tttgaatcct cagcggtctc cagtggc 27

<210> 565
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 565
aattctctat cggggcttct gtgtctgttg ctgggtccgc tttat 45

<210> 566
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 566
ctagataaaag cggaaccaggc aacagacaca gaagccccga tagag 45

<210> 567
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 567
ttttcttagag aggtgcacaa tgctctgg 28

<210> 568
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 108 -

<400> 568
tttgaattcc gtgtacagaa gcgagaagc 29

<210> 569
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 569
tttgccggccg ctagacttaa cctgagagat a 31

<210> 570
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 570
tttggggccca cgagagacag agacacttc 29

<210> 571
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 571
tttggggcccg ctcttcgctt ctgtacacg 29

<210> 572
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 572
gagaacgcgt gaccttccat 20

<210> 573
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 573
tccatgtcgg tcctgatgct 20

<210> 574
<211> 6
<212> DNA

- 109 -

<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 574
ctgtcg 6

<210> 575
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 575
tcgtga 6

<210> 576
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 576
cgtcga 6

<210> 577
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 577
agtgct 6

<210> 578
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 578
ctgtcg 6

<210> 579
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 579

- 110 -

agtgc	6
<210> 580	
<211> 6	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 580	
cgtcga	6
<210> 581	
<211> 6	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 581	
tcgtga	6
<210> 582	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 582	
gagaacgctc cagcttcgat	20
<210> 583	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 583	
gctagacgta agcgtga	17
<210> 584	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 584	
gagaacgctc gaccctccat	20
<210> 585	
<211> 21	
<212> DNA	
<213> Artificial Sequence	

- 111 -

<220>
<223> Synthetic Sequence

<400> 585
gagaacgctg gacctatccca t 21

<210> 586
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 586
gcttagagggtt agcgtga 17

<210> 587
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 587
gagaacgctg gacttccat 19

<210> 588
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 588
tcacgctaac gtcttagc 17

<210> 589
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 589
gcttagacggtt agcgtga 17

<210> 590
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 112 -

<223> Synthetic Sequence

<400> 590
atggaaaggc gagcggttctc 20

<210> 591
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 591
gagaacgctg gaccttcgat 20

<210> 592
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 592
gagaacgatg gaccttccat 20

<210> 593
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 593
gagaacgctg gatccat 17

<210> 594
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 594
gagaacgctc cagcaactgat 20

<210> 595
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 595
tccatgtcgg tcctgctgat 20

<210> 596

- 113 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 596
atgtcctcg 20
tcctgatgct

<210> 597
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 597
gagaacgctc 20
caccttccat

<210> 598
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 598
gagaacgctg 20
gaccttcgta

<210> 599
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 599
atggaagg 20
tc cgttctc

<210> 600
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 600
tcctga 6
6

<210> 601
<211> 8
<212> DNA

- 114 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 601
tcaacgtt 8

<210> 602
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 602
aacgtt 6

<210> 603
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 603
aacgttga 8

<210> 604
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 604
tcacgctaac ctcttagc 17

<210> 605
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 605
gagaacgctg gaccttgcat 20

<210> 606
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 606

- 115 -

gctggaccaa ccat 14
<210> 607
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 607
gagaacgctg gacccatcc at 22
<210> 608
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 608
gagaacgctg gacgctcatc cat 23
<210> 609
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 609
aacgttgagg ggcatt 15
<210> 610
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 610
atgccctca acgtt 15
<210> 611
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 611
tcaacgttga 10
<210> 612
<211> 14
<212> DNA
<213> Artificial Sequence

- 116 -

<220>
<223> Synthetic Sequence

<400> 612
gctggacctt ccat 14

<210> 613
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 613
caacgtt 7

<210> 614
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 614
acaacgttga 10

<210> 615
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 615
tcacgt 6

<210> 616
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 616
tcaagctt 8

<210> 617
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 617
tcgtaca 6

- 117 -

<210> 618
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 618
aggatatac 8

<210> 619
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 619
tagacgttc 8

<210> 620
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 620
gacgtcat 8

<210> 621
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 621
ccatcgat 8

<210> 622
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 622
atcgatgt 8

<210> 623
<211> 8
<212> DNA
<213> Artificial Sequence

- 118 -

<220>
<223> Synthetic Sequence

<400> 623
atgcatgt 8

<210> 624
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 624
ccatgcat 8

<210> 625
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 625
agcgctga 8

<210> 626
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 626
tcagcgct 8

<210> 627
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 627
ctttcgat 8

<210> 628
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 628
gtgccgggt ctccggc 18

- 119 -

<210> 629
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 629
gctgtggggc ggctcctg 18

<210> 630
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 630
tcaacgtt 8

<210> 631
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 631
tcaacgtt 8

<210> 632
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 632
aacgttga 8

<210> 633
<211> 7
<212> DNA
<213> Artificial Sequence

- 120 -

<220>
<223> Synthetic Sequence

<400> 633
tcaacgt 7

<210> 634
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 634
aacgttg 7

<210> 635
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 635
cgacga 6

<210> 636
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 636
tcaacgtt 8

<210> 637
<211> 5
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 637
tcgga 5

<210> 638
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 638
agaacgtt 8

- 121 -

<210> 639
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 639
tcatcgat 8

<210> 640
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 640
taaacgtt 8

<210> 641
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 641
ccaacgtt 8

<210> 642
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 642
gctcga 6

<210> 643
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 643
cgacgt 6

<210> 644
<211> 6
<212> DNA
<213> Artificial Sequence

<220>

- 122 -

<223> Synthetic Sequence
<400> 644
cgtcgt 6
<210> 645
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 645
acgttgt 6
<210> 646
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 646
cgttcg 6
<210> 647
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 647
gagcaagctg gaccttccat 20
<210> 648
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 648
cgcgta 6
<210> 649
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 649
cgtacg 6
<210> 650

- 123 -

<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 650
tcaccggt 8

<210> 651
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 651
caagagatgc taacaatgca 20

<210> 652
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 652
acccatcaat agctctgtgc 20

<210> 653
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 653
ccatcgat 8

<210> 654
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 654
tcgacgta 8

<210> 655
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 124 -

<400> 655	
ctagcgct	8
<210> 656	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 656	
taagcgct	8
<210> 657	
<211> 13	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 657	
tgcgcaattc gcg	13
<210> 658	
<211> 19	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 658	
atggaaggtc cagcggttct	19
<210> 659	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 659	
actggacgtt agcggtga	17
<210> 660	
<211> 18	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 660	
cgcctggggc tggctctgg	18
<210> 661	
<211> 18	

- 125 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 661
gtgtcggggt ctccgggc 18

<210> 662
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 662
gtgccggggt ctccgggc 18

<210> 663
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 663
cgccgtcgcg gcggttgg 18

<210> 664
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 664
gaagttcacg ttgaggggca t 21

<210> 665
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 665
atctggtag ggcaagctat g 21

<210> 666
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 126 -

<400> 666
gttgaaccc gagaacatca t 21

<210> 667
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 667
gcaacgtt 8

<210> 668
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 668
gtaacgtt 8

<210> 669
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 669
cgaacgtt 8

<210> 670
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 670
gaaacgtt 8

<210> 671
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 671
caaacgtt 8

<210> 672
<211> 8
<212> DNA

- 127 -

<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 672
ctaacgtt 8

<210> 673
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 673
ggaacgtt 8

<210> 674
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 674
tgaacgtt 8

<210> 675
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 675
acaacgtt 8

<210> 676
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 676
ttaacgtt 8

<210> 677
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 677

- 128 -

aaaacgtt	8
<210> 678	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 678	
ataaacgtt	8
<210> 679	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 679	
aacgttct	8
<210> 680	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 680	
tccgatcg	8
<210> 681	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 681	
tccgtacg	8
<210> 682	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 682	
gctagacgct agcgtga	17
<210> 683	
<211> 25	
<212> DNA	
<213> Artificial Sequence	

- 129 -

<220>	
<223> Synthetic Sequence	
<400> 683	
gagaacgctg gacctcatca tccat	25
<210> 684	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 684	
gagaacgcta gaccttctat	20
<210> 685	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 685	
actagacgtt agtgtga	17
<210> 686	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 686	
cacacaccttgg tcaatgtcac gt	22
<210> 687	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 687	
tctccatcct atggtttat cg	22
<210> 688	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 688	
cgctggacct tccat	15

- 130 -

<210> 689
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 689
caccaccccttg gtcaatgtca cgt 23

<210> 690
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 690
gctagacgtt agctgga 17

<210> 691
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 691
agtgcgattg cagatcg 17

<210> 692
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 692
ttttcgaaaa ttggaaaaaa ggtt 24

<210> 693
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 693
ttttcgaaaa tcgtttgtc gtt 23

<210> 694
<211> 24
<212> DNA
<213> Artificial Sequence

- 131 -

<220>
<223> Synthetic Sequence

<400> 694
tttttgtttt gtggttttgt ggtt 24

<210> 695
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 695
accgcatgga ttcttaggccaa 20

<210> 696
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 696
gctagacgtt agcgt 15

<210> 697
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 697
aacgctggac cttccat 17

<210> 698
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 698
tcaangtt 8

<210> 699
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 132 -

<400> 699
ccttcgat 8

<210> 700
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 700
actagacgtt agtgtga 17

<210> 701
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 701
gcttagagggtt agcgtga 17

<210> 702
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 702
atggactctc cagcggttctc 20

<210> 703
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 703
atcgactctc gagcggttctc 20

<210> 704
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 704
gcttagacgtt agc 13

<210> 705
<211> 9

- 133 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 705
gcttagacgt 9

<210> 706
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 706
agtgcgattc gagatcg 17

<210> 707
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 707
tcagngct 8

<210> 708
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 708
ctgattgctc tctcgtga 18

<210> 709
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 709
tnaacgtt 8

- 134 -

<210> 710
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 710
gagaangctg gaccttccat 20

<210> 711
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 711
gctagacgtt aggctga 17

<210> 712
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 712
gctacttagc gtga 14

<210> 713
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 713
gctacaccttag cgtga 15

<210> 714
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 714
atcgacttcg agcgttctc 19

<210> 715
<211> 20

- 135 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 715
atgcactctg cagcggttctc 20

<210> 716
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 716
agtgactctc cagcggttctc 20

<210> 717
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 717
gccagatgtt agctggaa 17

<210> 718
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 718
atcgactcga gcgttctc 18

<210> 719
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 719
atcgatcgag cgttctc 17

<210> 720
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)

- 136 -

<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 720
gagaacgctc gaccttcgat 20

<210> 721
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 721
gctagacgtt agctggaa 17

<210> 722
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 722
atcgactctc gagcgttctc 20

<210> 723
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 723
tagacgttag cgtga 15

<210> 724
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 724
cgactctcga gcgttctc 18

<210> 725
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 725
ggggtcgacc ttggaggggg g 21

- 137 -

<210> 726
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 726
gctaacgtta gcgtga 16

<210> 727
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 727
cgtcgtcgt 9

<210> 728
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (14)...(14)
<223> m5c

<223> Synthetic Sequence

<400> 728
gagaacgctg gacnttccat 20

<210> 729
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (18)...(18)
<223> m5c

<223> Synthetic Sequence

<400> 729
atcgacctac gtgcgttnnc 20

<210> 730
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (3)...(3)

- 138 -

<223> m5c

<223> Synthetic Sequence

<400> 730
atngacctac gtgcgttctc 20

<210> 731
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 731
gcttagangtt agcgt 15

<210> 732
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (14)...(14)
<223> m5c

<223> Synthetic Sequence

<400> 732
atcgactctc gagngttctc 20

<210> 733
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 733
ggggtaatgc atcagggggg 20

<210> 734
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 734
ggctgtattc ctgactgccc 20

<210> 735
<211> 17

- 139 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 735
ccatgctaac ctcttagc 17

<210> 736
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 736
gctagatgtt agcgtga 17

<210> 737
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 737
cgtacaccttac ggtga 15

<210> 738
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 738
tccatgctgg tcctgatgct 20

<210> 739
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 739
atcgactctc tcgagcgttc tc 22

<210> 740
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 140 -

<400> 740
gctagagtt agcggtga

17

<210> 741
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 741
atcgactctc gagtggttctc

20

<210> 742
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 742
aacgctcgac cttcgat

17

<210> 743
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 743
ctcaacgctg gaccttccat

20

<210> 744
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 744
atcgacctac gtgcgttctc

20

<210> 745
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 745
gagaatgctg gaccttccat

20

<210> 746
<211> 17
<212> DNA

- 141 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 746
tcacgctaac ctctgac 17

<210> 747
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 747
gagaacgctc cagcactgat 20

<210> 748
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 748
gagcaagctg gaccttccat 20

<210> 749
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 749
cgcttagaggt tagcgtga 18

<210> 750
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 750
gctagatgtt aacgt 15

<210> 751

- 142 -

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 751
atggaaggc cacgttctc 19

<210> 752
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 752
gctagatgtt agcgt 15

<210> 753
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 753
gctagacgtt agtgt 15

<210> 754
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 754
tccatgacgg tcctgatgct 20

<210> 755
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 755
tccatggcgg tcctgatgct 20

<210> 756
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 143 -

<400> 756
gctagacgat agcgt 15

<210> 757
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 757
gctagtcgat agcgt 15

<210> 758
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 758
tccatgacgt tcctgatgct 20

<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 759
tccatgtcgt tcctgatgct 20

<210> 760
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (13)...(13)
<223> m5c

<223> Synthetic Sequence

<400> 760
gctagacgtt agngt 15

<210> 761
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 761

- 144 -

gctaggcggtt agcgt 15
<210> 762
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 762
tccatgtngg tcctgatgct 20
<210> 763
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (12)...(12)
<223> m5c

<223> Synthetic Sequence

<400> 763
tccatgtcgg tnctgatgct 20
<210> 764
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified base
<222> (3)...(3)
<223> m5c

<221> modified base
<222> (10)...(10)
<223> m5c

<221> modified base
<222> (14)...(14)
<223> m5c

<400> 764
atngactctn gagngttctc 20
<210> 765
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 145 -

<223> Synthetic Sequence

<400> 765
atggaaggta cagtgttctc 20

<210> 766
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 766
gcatgacgtt gagct 15

<210> 767
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 767
ggggtcaacg ttgaggggg 20

<210> 768
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 768
ggggtcaagt ctgaggggg 20

<210> 769
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 769
cgcgcgcg cgcgcgcg 20

<210> 770
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 770
ccccccccccccc cccccccccccccc 28

<210> 771

- 146 -

<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 771
cccccccccc cccccccccc ccccccccccc ccccc 35

<210> 772
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 772
tccatgtcgc tcctgatcct 20

<210> 773
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 773
gctaaacgtt agcggt 15

<210> 774
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 774
tccatgtcga tcctgatgct 20

<210> 775
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 775
tccatgccgg tcctgatgct 20

<210> 776
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 147 -

<400> 776
aaaatcaacg ttgaaaaaaaaaa 20

<210> 777
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 777
tccataaacgt tcctgatgct 20

<210> 778
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 778
tggaggtccc accgagatcg gag 23

<210> 779
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 779
cgtcgtcgtc gtcgtcgatcg t 21

<210> 780
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 780
ctgctgctgc tgctgctgct g 21

<210> 781
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 781
gagaacgctc cgacacctcgta t 21

<210> 782
<211> 15

- 148 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 782
gctagatgtt agcgt 15

<210> 783
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 783
gcatgacgtt gagct 15

<210> 784
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 784
tcaatgctga 10

<210> 785
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 785
tcaacgttga 10

<210> 786
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

- 149 -

<400> 786
tcaacgttga 10

<210> 787
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 787
gcaatattgc 10

<210> 788
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 788
gcaatattgc 10

<210> 789
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 789
agttgcaact 10

<210> 790
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 790
tcttcgaa 8

<210> 791
<211> 8
<212> DNA
<213> Artificial Sequence

- 150 -

- 151 -

<210> 797
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 797
ggtgtgttag gttttgg 17

<210> 798
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 798
gagaangctc gacattcgat 20

<210> 799
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 799
tcaacgttaa cgtaaacgtt 20

<210> 800
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 800
gagcaagntg gacattccat 20

<210> 801

- 152 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 801
gagaangctc cagcaactgat 20

<210> 802
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 802
tcaangttga 10

<210> 803
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 803
gnaatattgc 10

<210> 804
<211> 24
<212> DNA
<213> Artificial Sequence

- 153 -

<220>
<223> Synthetic Sequence

<400> 804
tgctgtttt gtcgttttgt gctt 24

<210> 805
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 805
ctgcgttagc aatttaactg tg 22

<210> 806
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 806
tccatgacgt tcctgatgct 20

<210> 807
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 807
tgcatgccgt gcatccgtac acagctct 28

<210> 808
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 808
tgcatgccgt acacagctct 20

<210> 809
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 809
tgcatcagct ct 12

- 154 -

<210> 810
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 810
tgcgctct 8

<210> 811
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 811
cccccccccc cccccccccc 20

<210> 812
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 812
cccccccccc cc 12

<210> 813
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 813
cccccccc 8

<210> 814
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 814
tgcatcagct ct 12

<210> 815
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 155 -

<223> Synthetic Sequence

<400> 815
tgcatgccgt acacagctct 20

<210> 816
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 816
gagcaagctg gaccttccat 20

<210> 817
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 817
tcaaacgttaa cgttaacgtt aacgttaacg tt 32

<210> 818
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 818
gagaacgcgtc gaccttcgat 20

<210> 819
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 819
gtccccattt cccagaggag gaaat 25

<210> 820
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 820
ctagcggctg acgtcatcaa gctag 25

<210> 821

- 156 -

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 821
ctagcttgat gacggtcagcc gctag 25

<210> 822
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 822
cggtgcgtcatcaa 16

<210> 823
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 823
ctgacgtg 8

<210> 824
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 824
ctgacgtcat 10

<210> 825
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 825
attcgatcg ggcggggcga g 21

<210> 826
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 157 -

<400> 826	
ctcgcccccgc cccgatcgaa t	21
<210> 827	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 827	
gactgacgtc agcgt	15
<210> 828	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 828	
ctagccggctg acgtcataaaa gctagc	26
<210> 829	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 829	
ctagctttat gacgtcagcc gctagc	26
<210> 830	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 830	
ctagccggctg agctcataaaa gctagc	26
<210> 831	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 831	
ctagtggctg acgtcatcaa gctag	25
<210> 832	
<211> 20	

- 158 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 832
tccaccacgt ggtctatgct 20

<210> 833
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 833
ggaaatgaaa gattttatta taag 24

<210> 834
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 834
tctaaaaacc atctattctt aaccct 26

<210> 835
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 835
agctcaacgt catgc 15

<210> 836
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 836
ttaacggtgtt tagcggtatt ggtc 24

<210> 837
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 159 -

<400> 837
ttaagaccaa taccgctacc accg 24

<210> 838
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 838
gatctagtga tgagtcagcc ggatc 25

<210> 839
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 839
gatccggctg actcatcaact agatc 25

<210> 840
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 840
tccaagacgt tcctgatgct 20

<210> 841
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 841
tccatgacgt ccctgatgct 20

<210> 842
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 842
tccaccacgt ggctgatgct 20

<210> 843
<211> 17
<212> DNA

- 160 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 843
ccacgtggac ctctagc 17

<210> 844
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 844
tcagaccacg tggtcgggtg ttccctga 27

<210> 845
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 845
tcaggaacac ccgaccacgt ggtctga 27

<210> 846
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 846
cattttccacg atttccca 18

<210> 847
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 847
ttcctctctg caagagact 19

<210> 848
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 848

- 161 -

tgtatctctc tgaaggact	19
<210> 849	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 849	
ataaaagcgaa actagcagca gtttc	25
<210> 850	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 850	
gaaaactgctg cttagttcgc tttat	25
<210> 851	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 851	
tgcccaaaga ggaaaatttg tttcatacag	30
<210> 852	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 852	
ctgtatgaaa caaattttcc tccttggca	30
<210> 853	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 853	
ttagggtag gtttagggtt	20
<210> 854	
<211> 20	
<212> DNA	
<213> Artificial Sequence	

- 162 -

<220>
<223> Synthetic Sequence

<400> 854
tccatgagct tcctgatgct 20

<210> 855
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 855
aaaacatgac gttcaaaaaa 20

<210> 856
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 856
aaaacatgac gttcgggggg 20

<210> 857
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 857
ggggcatgag cttcgggggg 20

<210> 858
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 858
ctaggctgac gtcatcaagc tagt 24

<210> 859
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 859
tctgacgtca tctgacgttg gctgacgtct 30

- 163 -

<210> 860
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 860
ggaatttagta atagatata tag aagttt 25

<210> 861
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 861
tttacacctttt ataaacataaa ctaaaaacaaa 30

<210> 862
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 862
gcgtttttttt ttgcgt 15

<210> 863
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 863
atatctaatac aaaacattaa caaa 24

<210> 864
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 864
tctatccccag gtgggttccttg ttag 24

<210> 865
<211> 20
<212> DNA
<213> Artificial Sequence

- 164 -

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 865
tccatgacgt tcctgatgtc 20

<210> 866
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 866
tccatgagct tcctgatgtc 20

<210> 867
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (11)...(13)
<223> Conjugated to FITC moiety.

<221> misc_feature
<222> (0)...(0)
<223> Has phosphodiester backbone.

<223> Synthetic Sequence

<400> 867
tttttttttt ttt 13

<210> 868
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (11)...(13)
<223> Conjugated to biotin moiety.

<221> misc_feature
<222> (0)...(0)
<223> Has phosphorothioate and phosphodiester chimeric backbone with phosphodiester on 3' end.

<223> Synthetic Sequence

- 165 -

<400> 868
ttttttttt ttt 13

<210> 869
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 869
ctagttgat gagtcagcc gctag 25

<210> 870
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 870
ttcagttgtc ttgctgctta gctaa 25

<210> 871
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 871
tccatgagct tcctgagtc 20

<210> 872
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 872
ctagggctg acgtcatcaa tctag 25

<210> 873
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 873
tgcttagctgt gcctgtacct 20

<210> 874
<211> 23
<212> DNA

- 166 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 874
atgctaaagg acgtcacatt gca 23

<210> 875
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 875
tgcaatgtga cgtcctttag cat 23

<210> 876
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 876
gttagggact ttccgagctc gagatcctat g 31

<210> 877
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 877
cataggatct cgagctcgga aagtccccta c 31

<210> 878
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 878
ctgtcagggaa ctgcaggtaa gg 22

<210> 879
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 879

- 167 -

cataacatag gaatatttac tcctcgc	27
<210> 880	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 880	
ctccagctcc aagaaaggac g	21
<210> 881	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 881	
gaagtttctg gtaagtcttc g	21
<210> 882	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 882	
tgctgctttt gtgttttgt gctt	24
<210> 883	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 883	
tcgtcggtttt gtgggttttgt ggtt	24
<210> 884	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 884	
tcgtcggtttt tcgttttgtc gtt	23
<210> 885	
<211> 22	
<212> DNA	
<213> Artificial Sequence	

- 168 -

<220>
<223> Synthetic Sequence

<400> 885
tcctgacgtt cggcgccgc cc 22

<210> 886
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 886
tgctgctttt gtgcttttgt gctt 24

<210> 887
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 887
tccatgagct tcctgagtt 20

<210> 888
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 888
tcgtcgtttc gtcgtttga cgtt 24

<210> 889
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 889
tcgtcgtttg cgtgcgtttc gtcgtt 26

<210> 890
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 890
tcgcgtgcgt tttgtcgtt tgacgtt 27

- 169 -

<210> 891
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 891
ttcgtcggtt tgcgttttg tcggtt 25

<210> 892
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 892
tcctgacggg gaagt 15

<210> 893
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 893
tcctggcgtg gaagt 15

<210> 894
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 894
tcctggcgtt gaagt 15

<210> 895
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 895
tcctggcgtt gaagt 15

<210> 896
<211> 15
<212> DNA
<213> Artificial Sequence

- 170 -

<220>
<223> Synthetic Sequence

<400> 896
tcctgacgtg gaagt 15

<210> 897
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 897
gcgacgttcg gcgcgccccc 20

<210> 898
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 898
gcgacgggctcg gcgcgccccc 20

<210> 899
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 899
gcggcgtgcg gcgcgccccc 20

<210> 900
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 900
gcggcggtcg gcgcgccccc 20

<210> 901
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 901
gcgacggctcg gcgcgccccc 20

- 171 -

<210> 902
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 902
gcggcggttcg gcgcgcgc
20

<210> 903
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 903
gcgacgtgcg ggcgcgc
20

<210> 904
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 904
tcgtcgctgt ctccg
15

<210> 905
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 905
tgtgggggtt ttgggtttgg
20

<210> 906
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 906
aggggaggagg
20

<210> 907
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

- 172 -

<223> Synthetic Sequence

<400> 907
tgtgtgtgtg tgtgtgtgtg t 21

<210> 908
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 908
ctctctctct ctctctctct ct 22

<210> 909
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 909
ggggtcgacg tcgagggggg 20

<210> 910
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 910
atatatatat atatatatat at 22

<210> 911
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 911
ttttttttt tttttttttt tttttttt 27

<210> 912
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 912
ttttttttt tttttttttt t 21

<210> 913

- 173 -

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 913
ttttttttt tttttttt 18

<210> 914
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 914
gctagagggg agggt 15

<210> 915
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 915
gctagatgtt agggg 15

<210> 916
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 916
gcatgagggg gagct 15

<210> 917
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 917
atggaaggc cagggggctc 20

<210> 918
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 174 -

<400> 918
atggactctg gagggggc
20
<210> 919
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 919
atgaaaggc caagggc
20
<210> 920
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 920
gagaagggg gacttggat
20
<210> 921
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 921
gagaagggg gaccttccat
20
<210> 922
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 922
gagaaggggc cagcactgat
20
<210> 923
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 923
tccatgtgg gcctgatgct
20
<210> 924
<211> 20

- 175 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 924
tccatgaggg gcctgatgct 20

<210> 925
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 925
tccatgtggg gcctgctgat 20

<210> 926
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 926
atggactctc cggggttctc 20

<210> 927
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 927
atggaaggtc cggggttctc 20

<210> 928
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 928
atggactctg gaggggtctc 20

<210> 929
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 176 -

<400> 929
atggaggctc catggggctc 20

<210> 930
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 930
atggactctg gggggttctc 20

<210> 931
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 931
tccatgtggg tggggatgct 20

<210> 932
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 932
tccatgcggg tggggatgct 20

<210> 933
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 933
tccatggggg tcctgatgct 20

<210> 934
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 934
tccatgggt ccctgatgct 20

<210> 935
<211> 20
<212> DNA

- 177 -

<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 935
tccatgggt gcctgatgct 20

<210> 936
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 936
tccatgggt tcctgatgct 20

<210> 937
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 937
tccatcgaaa gcctgatgct 20

<210> 938
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 938
gctagaggaa gtgt 14

<210> 939
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 939
ttttttttt tttttttt 18

<210> 940
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (2)...(2)
<223> m is a or c

- 178 -

<221> misc_difference
<222> (18)...(18)
<223> m is a or c

<223> Synthetic Sequence

<400> 940
g~~m~~gggtcaacg ttgagggm~~gg~~ g 21

<210> 941
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 941
ggggagttcg ttgagggggg g 21

<210> 942
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 942
tcgtcgttcc cccccccccc 20

<210> 943
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 943
ttggggggtt tttttttttt ttttt 25

<210> 944
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 944
tttaaattttt aaaatttaaa ata 23

<210> 945
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 179 -

<400> 945
ttggttttt ttgtttttt ttgg 24
<210> 946
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 946
tttccctttt cccctttcc cctc 24
<210> 947
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (21)...(21)
<223> s is g or c

<223> Synthetic Sequence

<400> 947
ggggtcatcg atgagggggg s 21
<210> 948
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 948
tccatgacgt tcctgacgtt 20
<210> 949
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 949
tccatgacgt tcctgacgtt 20
<210> 950
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 950

- 180 -

tccatgacgt tcctgacgtt 20

<210> 951
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 951
tccatgacgt tcctgacgtt 20

<210> 952
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 952
tccatgacgt tcctgacgtt 20

<210> 953
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 953
tccatgacgt tcctgacgtt 20

<210> 954
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 954
tccatgacgt tcctgacgtt 20

<210> 955
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 955
tccatgacgt tcctgacgtt 20

<210> 956
<211> 20
<212> DNA
<213> Artificial Sequence

- 181 -

<220>
<223> Synthetic Sequence

<400> 956
tccatgacgt tcctgacgtt 20

<210> 957
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 957
tccatgacgt tcctgacgtt 20

<210> 958
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 958
tccatgacgt tcctgacgtt 20

<210> 959
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 959
gggggacgat cgtcgaaaaa 19

<210> 960
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 960
gggggtcgta cgacgggggg 20

<210> 961
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 961
tttttttttt tttttttttt tttt 24

- 182 -

<210> 962
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 962
aaaaaaaaaaa aaaaaaaaaaa aaaa 24

<210> 963
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 963
ccccccccccc cccccccccc cccc 24

<210> 964
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 964
tcgtcgaaaa gtcgaaaaaa cgtt 24

<210> 965
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 965
tcgtcgaaaa gtcgaaaaaa cgtt 24

<210> 966
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 966
tcgtcgaaaa gtcgaaaaaa cgtt 24

<210> 967
<211> 24
<212> DNA
<213> Artificial Sequence

- 183 -

<220>
<223> Synthetic Sequence

<400> 967
tcgtcgttt gtcgttttgt cgtt 24

<210> 968
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 968
ggggtcaacg ttgaggggg 20

<210> 969
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 969
ggggtcaacg ttgaggggg 20

<210> 970
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 970
ggggtcaagc ttgaggggg 20

<210> 971
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 971
tgctgttcc cccccccccc 20

<210> 972
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 972
ggggacgtcg acgtgggggg 20

- 184 -

<210> 973
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 973
ggggtcgtcg acgagggggg 20

<210> 974
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 974
ggggtcgacg tacgtcgagg gggg 24

<210> 975
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 975
ggggaccggt accgggtgggg gg 22

<210> 976
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 976
gggtcgcacgt cgagggggg 19

<210> 977
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 977
ggggtcgacg tcgagggggg 19

<210> 978
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

- 185 -

<223> Synthetic Sequence

<400> 978
gggaaacgtt aacgttgggg gg 22

<210> 979
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 979
ggggtcaccg gtgagggggg 20

<210> 980
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 980
ggggtcgttc gaacgagggg gg 22

<210> 981
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 981
ggggacgttc gaacgtgggg gg 22

<210> 982
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 982
tcaactttga 10

<210> 983
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 983
tcaagcttga 10

<210> 984

- 186 -

<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 984
tcacgatcgt ga 12

<210> 985
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 985
tcagcatgct ga 12

<210> 986
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 986
gggggagcat gctggggggg 20

<210> 987
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 987
ggggggggggg gggggggggg 20

<210> 988
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 988
gggggacgat atcgatcgaaa gg 22

<210> 989
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 187 -

<400> 989 gggggacgac gtcgtcgggg gg	22
<210> 990 <211> 22 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 990 gggggacgag ctcgtcgggg gg	22
<210> 991 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 991 gggggacgta cgtcgggggg	20
<210> 992 <211> 8 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 992 tcaacgtt	8
<210> 993 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 993 tccataccgg tcctgatgt	20
<210> 994 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 994 tccataccgg tcctaccggt	20
<210> 995 <211> 20	

- 188 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 995
gggggacgat cgttgggggg 20

<210> 996
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 996
ggggaacgat cgtcgggggg 20

<210> 997
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 997
ggggggacga tcgtcgaaaa g 21

<210> 998
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 998
gggggacgat cgtcgggggg g 21

<210> 999
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 999
aaagacgtta aa 12

<210> 1000
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 189 -

<400> 1000
aaagagctta aa 12

<210> 1001
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 1001
aaagangtta aa 12

<210> 1002
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1002
aaattcggaa aa 12

<210> 1003
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1003
gggggtcatc gatgaggggg g 21

<210> 1004
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1004
gggggtcaac gttgaggggg g 21

<210> 1005
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1005
atgttagctta ataacaaaagc 20

- 190 -

<210> 1006
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1006
ggatcccttg agttaacttct 20

<210> 1007
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1007
ccattccact tctgattacc 20

<210> 1008
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1008
tatgtattat catgtagata 20

<210> 1009
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1009
agcctacgta ttccccctcc 20

<210> 1010
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1010
ttcctgcaac tactattgtta 20

<210> 1011
<211> 20
<212> DNA
<213> Artificial Sequence

- 191 -

<220>
<223> Synthetic Sequence

<400> 1011
atagaaggcc ctacaccagt 20

<210> 1012
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1012
ttacaccggc ctagggagg 20

<210> 1013
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1013
ctaaccagat caagtctagg 20

<210> 1014
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1014
cctagacttg atctggtag 20

<210> 1015
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1015
tataaggctc gtccgacatg 20

<210> 1016
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1016
catgtcgac gaggctata 20

- 192 -

<210> 1017
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1017
tggtggtggg gagtaagctc 20

<210> 1018
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1018
gagctactcc cccaccacca 20

<210> 1019
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1019
gccttcgatc ttctgtggga 20

<210> 1020
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1020
tggacttctc tttgccgtct 20

<210> 1021
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1021
atgctgttagc ccagcgataa 20

<210> 1022
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 193 -

<223> Synthetic Sequence

<400> 1022
accgaatcag cggaaagtga 20

<210> 1023
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1023
tccatgacgt tcctgacgtt 20

<210> 1024
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1024
ggagaaaaccc atgagctcat ctgg 24

<210> 1025
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1025
accacagacc agcaggcaga 20

<210> 1026
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1026
gagcgtgaac tgcgcgaaga 20

<210> 1027
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1027
tcggtaacct tgcagcggtt 20

<210> 1028

- 194 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1028
ctggagccct agccaaggat 20

<210> 1029
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1029
gcgactccat caccagcgat 20

<210> 1030
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1030
cctgaagtaa gaaccagatg t 21

<210> 1031
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1031
ctgtgttatac tgacatacac c 21

<210> 1032
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1032
aattagcctt aggtgattgg g 21

<210> 1033
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 195 -

<400> 1033
acatctggtt cttacttcag g 21
<210> 1034
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1034
ataagtcata ttttgggaac tac 23
<210> 1035
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1035
cccaatcacc taaggctaatt t 21
<210> 1036
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1036
ggggtcgtcg acgagggggg 20
<210> 1037
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1037
ggggtcgttc gaacgaggggg gg 22
<210> 1038
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1038
ggggacgttc gaacgtgggg gg 22
<210> 1039
<211> 15

- 196 -

<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (9)...(9)
<223> n is 5-methylcytosine.

<223> Synthetic Sequence

<400> 1039
tcctggcgng gaagt 15

<210> 1040
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1040
ggggaacgac gtcgttgggg gg 22

<210> 1041
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1041
ggggaacgta cgtcgggggg 20

<210> 1042
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1042
ggggaacgta cgtacgttgg gggg 24

<210> 1043
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1043
ggggtcacccg gtgagggggg 20

<210> 1044
<211> 24
<212> DNA
<213> Artificial Sequence

- 197 -

<220>
<223> Synthetic Sequence

<400> 1044
gggtcgacg tacgtcgagg gggg 24

<210> 1045
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1045
ggggaccgggt accgggtgggg gg 22

<210> 1046
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1046
gggtcgacgt cgagggggg 19

<210> 1047
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1047
gggtcgacg tcgaggggg 18

<210> 1048
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1048
ggggaacgtt aacgttgggg gg 22

<210> 1049
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1049
ggggacgtcg acgtggggg 19

- 198 -

<210> 1050
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1050
gcactttcg aagctacagc cggcagcctc tgat 34

<210> 1051
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1051
cggttcc atgaggcttt tgctaatctt gg 32

<210> 1052
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1052
cggttcc atgaaagtct ttggacgatg tgago 35

<210> 1053
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1053
tcctgcaggtaa 15

<210> 1054
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1054
gggggtcggtt cgttgggggg 20

<210> 1055
<211> 20
<212> DNA
<213> Artificial Sequence

- 199 -

<220>
<223> Synthetic Sequence

<400> 1055
gggggatgtat tgttgggggg 20

<210> 1056
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<221> modified_base
<222> (11)...(11)
<223> m5c

<223> Synthetic Sequence

<400> 1056
gggggangat ngttgggggg 20

<210> 1057
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1057
gggggagcta gcttgggggg 20

<210> 1058
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1058
ggttcttttg gtccttgct 20

<210> 1059
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1059
ggttcttttg gtcctcgct 20

<210> 1060
<211> 20
<212> DNA

- 200 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1060
ggttcttttg gtccttatct 20

<210> 1061
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1061
ggttcttggt ttccttgct 20

<210> 1062
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1062
tggcttttg gtccttgct 20

<210> 1063
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1063
ggttcaaatg gtccttgct 20

<210> 1064
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1064
gggtcttttg ggccttgct 20

<210> 1065
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1065

- 201 -

tccaggactt ctctcaggtt tttt 24

<210> 1066
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1066
tccaaaactt ctctcaaatt 20

<210> 1067
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1067
tactactttt atacttttat actt 24

<210> 1068
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1068
tgtgtgtgtg tgtgtgtgtg tgtg 24

<210> 1069
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1069
ttgttgttgt tgtttggtgt tgttg 25

<210> 1070
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1070
ggctccgggg agggaaatttt tgtctat 27

<210> 1071
<211> 19
<212> DNA
<213> Artificial Sequence

- 202 -

<220>
<223> Synthetic Sequence

<400> 1071
gggacgatcg tcggggggg 19

<210> 1072
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1072
gggtcgtcga cgagggggg 20

<210> 1073
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1073
ggtcgtcgac gaggggggg 19

<210> 1074
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1074
gggtcgtcgt cgtgggggg 20

<210> 1075
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1075
ggggacgatc gtcgggggg 20

<210> 1076
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1076
ggggacgatcg tcgtggggg 20

- 203 -

<210> 1077
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1077
ggggtcgacg tcgacgtcga ggggggg 27

<210> 1078
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1078
gggaaaccgc gtgtgggggg g 21

<210> 1079
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1079
ggggacgacg tcgtgggggg g 21

<210> 1080
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1080
tcgtcgtcgt cgtcggtgggg ggg 23

<210> 1081
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1081
tcctgccggg gaagt 15

<210> 1082
<211> 15
<212> DNA
<213> Artificial Sequence

- 204 -

<220>
<223> Synthetic Sequence

<400> 1082
tcctgcaggg gaagt 15

<210> 1083
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1083
tcctgaaggg gaagt 15

<210> 1084
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1084
tcctggcggg caagt 15

<210> 1085
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1085
tcctggcggg taagt 15

<210> 1086
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1086
tcctggcggg aaagt 15

<210> 1087
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1087
tccgggcggg gaagt 15

- 205 -

<210> 1088
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1088
tcggggcggg gaagt 15

<210> 1089
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1089
tcccgccggg gaagt 15

<210> 1090
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1090
gggggacgtt ggggg 15

<210> 1091
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1091
ggggtttttt ttttgggggg 20

<210> 1092
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1092
ggggccccccc ccccgggggg 20

<210> 1093
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

- 206 -

<223> Synthetic Sequence

<400> 1093

gggggttgttg ttgttgggg g

21

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.